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INTRODUCTION
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I. N-methyl-D-Aspartate receptors
 The amino acid L-glutamate is the principal excitatory neurotransmitter in the mammalian central 
nervous system (CNS). After its release from presynaptic nerve terminals, it interacts with a variety of 
receptors located in the neuronal membrane. According to the mechanism by which their activation 
generates the cellular response, glutamate receptors are classified into two broad categories: ionotropic 
and metabotropic. Ionotropic glutamate receptors (iGluRs) are nonselective ion channels that flux cati-
ons upon agonist binding, thus producing a depolarizing current. Metabotropic glutamate receptors 
(mGluRs) are G-protein-coupled receptors that, on binding glutamate, trigger intracellular signaling 
cascades following activation of the coupled G proteins. iGluRs can be subdivided into three large 
families (Traynelis et al., 2010) on the basis of agonist selectivity: N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) and kainate (KA). Since their discovery 
three decades ago, NMDA receptors (NMDARs) have kept fascinating neuroscientists because of their 
central roles in CNS function. NMDARs are cationic channels permeable to sodium (Na+), potassium 
(K+), and calcium (Ca2+) ions. They constitute the major portal for the entry of Ca2+ into the cell, Ca2+ 
being a vital second messenger that affects a wide range of cellular processes. These glutamate-gated 
ion channels are essential mediators of brain plasticity and are capable of converting specific patterns 
of neuronal activity into long-term changes in synapse structure and function that are thought to un-
derlie higher cognitive functions (Traynelis et al., 2010). NMDAR dysfunctions are also involved in 
various neurological and psychiatric disorders (Traynelis et al., 2010; C. G. Lau & Zukin, 2007; Mony, 
Kew, Gunthorpe, & Paoletti, 2009), including stroke, pathological pain, neurodegenerative diseases and 
schizophrenia, and there is growing interest in developing new drugs that target these receptors. Recent 
studies have highlighted the functional diversity of NMDARs (Traynelis et al., 2010; Cull-Candy & 
Leszkiewicz, 2004; Paoletti, 2011). NMDARs are diverse in their molecular (subunit) composition, their 
biophysical and pharmacological properties, their interacting partners and their subcellular localization. 
Subunit composition varies across CNS regions during development and in disease states (Traynelis et 
al., 2010; C. G. Lau & Zukin, 2007; Mony et al., 2009). There is also evidence that even at fully mature 
synapses, the NMDAR subunit content changes depending on neuronal activity (Paoletti, Bellone, & 
Zhou, 2013).
 I.1. NMDAR subunits
 Functional NMDARs are tetramers composed of different subunits, falling into three subfamilies 
according to sequence homology, have been identified (Traynelis et al., 2010; Cull-Candy & Lesz-
kiewicz, 2004; Paoletti, 2011) (Fig. 1A): the GluN1 subunit, four distinct GluN2 subunits (GluN2A, 
GluN2B, GluN2C and GluN2D), which are encoded by four different genes, and a pair of GluN3 
subunits (GluN3A and GluN3B), arising from two separate genes (Paoletti et al., 2013). Typically, en-
dogenous NMDARs are di-heteromers comprising two obligatory GluN1 subunits and two regulatory 
GluN2 or GluN3 subunits, which assemble as a dimer of dimers. However, NMDARs are also able to 
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assemble as tri-heteromers. Specifically, GluN1/GluN2B/GluN3A or GluN1/GluN2B/GluN2D 
complexes are expressed at early stages of development and GluN1/GluN2A/GluN2B or GluN1/
GluN2A/GluN2C in adult-hood (Al-Hallaq, Conrads, Veenstra, & Wenthold, 2007; Brothwell et al., 
2008).
 The total number of amino acids per subunit ranges from 900 to over 1,480. The difference in 
subunit size is almost entirely accounted for by differences in the length of the intracellular carboxyl 
(C)-terminal domain (CTD), a region that is involved in receptor trafficking and couples receptors to 
signaling cascades (Traynelis et al., 2010). 
 The existence of a large repertoire of homologous NMDAR subunits allows for various combi-
nations of subunit assembly, which leads to a multiplicity of receptor subtypes in the CNS (Fig. 1B & 
C).The GluN1 subunit is encoded by a single gene but has eight distinct isoforms (GluN1-1a–GluN1-
4a and GluN1-1b–GluN1-4b) owing to alternative splicing (Fig. 1A) (Paoletti et al., 2013). The GluN1-
b isoforms (or exon 5-containing isoforms) possess an additional extracellular 21 amino-acids stretch 
(known as the N1 cassette) that affects the receptor’s gating and pharmacological properties (Rum-
baugh, Prybylowski, Wang, & Vicini, 2000; Vance, Hansen, & Traynelis, 2012). The four other splice 
variants arise from alternative splicing of exon 21 and exon 22, creating CTDs of variable length and 
differential subunit trafficking properties (Horak & Wenthold, 2009).
Fig. 1: NMDAR subunit diversity. (A) 7 NMDAR subunits have been identified: GluN1, GluN2A-GluN2D and 
GluN3A-GluN3B. It exists alternative splicing of GluN1 and GluN3A subunits increasing the NMDAR  subunit 
heterogeneity. M1-M4 indicate membrane segments. (Paoletti, Bellone, & Zhou, 2013).
(B) Di-heteromeric NMDARs thought to exist in CNS. (Paoletti, Bellone, & Zhou, 2013).
(C) Tri-heteromeric NMDARs thought to exist in CNS (Paoletti, Bellone, & Zhou, 2013).
A. B.
C.
 I.2. Subunit architecture and operation
 Similar to all other iGluR subunits, NMDAR subunits consist of four discrete modules (Traynelis 
et al., 2010; Paoletti, 2011; Mayer, 2011) (Fig. 2): in the extracellular region there are a tandem of large 
globular bilobate (or clamshell-like) domains comprising the amino (N)-terminal domain (NTD), which 
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is involved in subunit assembly and allosteric regulation, and the agonist-binding domain (ABD) that is 
formed by two discontinuous segments (S1 and S2), which binds glycine (or D-serine) in GluN1 and 
GluN3 subunits and glutamate in GluN2 subunits; the transmembrane domain (TMD) made of three 
transmembrane helices (M1, M3 and M4) plus a re-entrant pore loop (M2) that lines the ion selectivity 
filter; and an intracellular CTD, which is involved in receptor trafficking, anchoring and coupling to sig-
naling molecules (Paoletti et al., 2013). Although the structure of a full NMDAR is still lacking, several 
high-resolution crystal structures of isolated NTDs (Karakas, Simorowski, & Furukawa, 2011) and 
ABDs (Hiroyasu Furukawa, Singh, Mancusso, & Gouaux, 2005) captured in different conformational 
states are available. Within a tetrameric receptor complex, the NTDs and ABDs assemble as dimers, 
with the full receptor operating as a dimer-of-dimers. In ‘classical’ GluN1/GluN2 receptors, the two 
constitutive GluN1/GluN2 dimers adopt an alternating GluN1/GluN2/GluN1/GluN2 subunit ar-
rangement around the pore (Salussolia, Prodromou, Borker, & Wollmuth, 2011; Riou, Stroebel, Ed-
wardson, & Paoletti, 2012).
Fig. 2:  NMDAR subunit structure. Each GluN subunits are made out of four distinct domains: the N-terminal domain 
(NTD), the agonist-binding domain (ABD), the transmembrane domain (TMD) containing the ion channel, and an 
intracellular C-terminal domain (CTD) (Paoletti, Bellone, & Zhou, 2013).
 NMDARs probably have a comparable ‘layer’ organization to that of AMPA receptors (AM-
PARs) (Sobolevsky, Rosconi, & Gouaux, 2009) in which the ABDs are sandwiched between the TMD 
at the "bottom" and the NTDs at the "top" (Fig. 3). The basic gating principles that involve agonist-
induced closure of the ABDs are also conserved between iGluR families (Paoletti, 2011); Mayer, 2011). 
By contrast, NMDAR NTDs have a unique twisted clam-shell conformation (Karakas et al., 2011), re-
sulting in looser NTD dimer assemblies than the tightly packed AMPA and kainate NTD dimers. In 
agreement, structural rearrangements occurring distally at the NTD level can be sensed by the down-
stream gating machinery (Karakas et al., 2011; Gielen et al., 2008; Gielen, Siegler Retchless, Mony, 
Johnson, & Paoletti, 2009). The dynamic nature of NMDAR NTDs, together with their ability to rec-
ognize a host of small ligands acting as subunit-specific allosteric modulators, confers a central role of 
the N-terminal region in generating functional and pharmacological diversity in the NMDAR family.
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Fig. 3: Multiple binding sites of NMDAR.  NMDARs contain multiple binding sites for extracellular small-molecule 
ligands acting as subunit-selective allosteric modulators. A model of a GluN1/GluN2 heterodimer based on the X-ray 
crystal structures of GluN1/GluN2B NTDs (Karakas et al., 2011), GluN1/GluN2A ABDs (Furukawa et al., 2005) and 
the AMPA receptor GluA2 pore region (Sobolevsky, Rosconi, & Gouaux, 2009) is shown. The + and - signs indicate 
positive and negative allosteric modulators, respectively (Paoletti, Bellone, & Zhou, 2013).
 I.3. Subunit expression profile
  In accordance with the widespread CNS distribution of NMDARs, the obligatory GluN1 subunit 
is ubiquitously expressed from embryonic stage E14 to adulthood (Watanabe, Inoue, Sakimura, & 
Mishina, 1992; Akazawa, Shigemoto, Bessho, Nakanishi, & Mizuno, 1994; Monyer, Burnashev, Laurie, 
Sakmann, & Seeburg, 1994). There are specific differences in GluN1 isoform expression however 
(Paoletti, 2011). Whereas GluN1-2 is widely distributed, GluN1-1 and GluN1-4 have a complementary 
distribution: the former is concentrated in more rostral regions (including the cortex and hippocam-
pus). The GluN1-a and GluN1-b isoforms have largely overlapping expression patterns but their rela-
tive abundance varies from one region to another. Notably, in the hippocampus, GluN1-a isoforms are 
found in all principal cells, whereas the GluN1-b isoforms are largely restricted to the CA3 layer (Laurie 
& Seeburg, 1994). However, the functional significance of the differential expression of GluN1 iso-
forms remains unclear. 
 The four GluN2 subunits, which are major determinants of the receptor’s functional heterogene-
ity, show strikingly different spatiotemporal expression profiles (Akazawa et al., 1994; Monyer et al., 
1994; Sheng, Cummings, Roldan, Jan, & Jan, 1994) (Fig. 4). In the embryonic brain, only GluN2B and 
GluN2D subunits are expressed, and the latter is mostly found in caudal regions. Major changes in the 
expression patterns of the GluN2 subunits occur during the first 2 postnatal weeks. GluN2A expres-
sion starts shortly after birth and rises steadily to become widely and abundantly expressed in virtually 
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every CNS area in the adult. Concomitant to this progressive rise in GluN2A expression, GluN2D ex-
pression drops markedly, and in the adult, it is expressed at low levels mostly in the diencephalon and 
mesencephalon. In sharp contrast to GluN2D expression, GluN2B expression is maintained at high 
levels following birth, peaks around the first postnatal week and becomes progressively restricted to the 
forebrain. Lastly, expression of GluN2C appears late in development (postnatal day 10 (P10)), and its 
expression is mainly confined to the cerebellum and the olfactory bulb. The GluN3A and GluN3B 
subunits also display differential ontogenetic profiles (Henson, Roberts, Pérez-Otaño, & Philpot, 2010; 
Pachernegg, Strutz-Seebohm, & Hollmann, 2012) (Fig. 4). GluN3A expression peaks in early postnatal 
life and then declines progressively. Conversely, GluN3B expression slowly increases throughout devel-
opment, and in the adult, it is expressed at high levels in motor neurons and possibly other regions. The 
specific expression of GluN2B, GluN2D and GluN3A subunits early in development strongly suggests 
that these subunits are important for synaptogenesis and synaptic maturation (Henson et al., 2010; 
Pachernegg et al., 2012; Paoletti et al., 2013). In the adult CNS, particularly in higher brain structures 
(such as the hippocampus and cortex), GluN2A and GluN2B are the predominant subunits (Watanabe 
et al., 1992; Akazawa et al., 1994; Monyer et al., 1994), indicating that they have central roles in synaptic 
function and plasticity. 
Fig. 4: NMDAR subunit expression from birth to adulthood. The development profile of GluN subunit expression 
in the mouse brain at day of birth (postnatal day 0 (P0)), 2 weeks following birth (P14) and at adult stage (Paoletti et al., 
2013).
 The developmental increase in the GluN2A/GluN2B ratio (also referred to as "GluN2B to 
GluN2A switch") is thought to play a critical role in postnatal brain development, by optimizing the 
threshold for synaptic plasticity induction at different developmental points via the unique biophysical 
and signaling properties of GluN2A and GluN2B (Yashiro & Philpot, 2008). GluN2A/GluN2B ratios 
can be bidirectionally regulated by experimental manipulations in neuronal activity levels in vitro (Ehlers, 
2003; Bellone & Nicoll, 2007) and in vivo sensory experience (Nase, Weishaupt, Stern, Singer, & Mo-
nyer, 1999). For instance, visual deprivation reduces the developmental shift in the GluN2A/GluN2B 
ratio in the primary visual cortex (Quinlan, Olstein, & Bear, 1999a; Philpot, Sekhar, Shouval, & Bear, 
2001). Several studies indicate that the elevation in the GluN2A/GluN2B ratio regulates the end of the 
critical period plasticity across various brain areas (Carmignoto & Vicini, 1992; X.-B. Liu, Murray, & 
Jones, 2004; Erisir & Harris, 2003). Given the differential characteristics of GluN2 subunits, it is likely 
that a synapse with a high GluN2A content exhibits a reduced window for spike-timing plasticity, inte-
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grating stimuli received in a shorter period of time than a synapse with a reduced GluN2A/B ratio. 
This may limit the formation of inappropriate synapses by reducing synaptic response time. In addi-
tion, the threshold for LTP induction is elevated in these synapses, making their potentiation more dif-
ficult. It may be that the elevated threshold for LTP could play a role in the pruning of excess synapses 
formed in the initial developmental stages, as it has been reported that synapses that are not activated 
are eliminated (M. Yasuda et al., 2011).
 There are also important differences in the subcellular expression of the NMDAR subunits. For 
example, GluN1 exists in two pool: a population in the plasma membrane, assembled with GluN2 or 
GluN3 subunits, and another pool retained in the ER with a short half-life. GluN1 retention in the ER 
is modulated by alternative splicing and PKC phosphorylation. In contrast, GluN2 subunits are mainly 
localized at the plasma membrane. Although there are some reports of presynaptic NMDARs (Corlew, 
Brasier, Feldman, & Philpot, 2008), typically NMDARs are localized at postsynaptic sites throughout 
the CNS. The current simplified model is that GluN2A-containing NMDARs are predominantly ex-
pressed at synaptic sites, whereas GluN2B-containing NMDARs are enriched at extrasynaptic sites in 
the adult CNS (Groc, Bard, & Choquet, 2009).
 I.4. NMDAR functional properties
 NMDARs exhibit a number of properties that are unique among glutamate receptors. First, their 
activation requires simultaneous binding of glutamate and a coagonist. Although glycine was first iden-
tified as a coagonist of NMDARs (Johnson & Ascher, 1987), D-serine has been proposed as the major 
endogenous coagonist of synaptic NMDARs at several CNS synapses (Henneberger, Papouin, Oliet, & 
Rusakov, 2010; Mothet et al., 2000). Recently, Papouin et al. (2012) used enzymatic degradation of ei-
ther coagonist in hippocampal slices from adult rats to demonstrate that D-serine is the coagonist at 
synaptic receptors while glycine acts at extrasynaptic NMDARs (Papouin et al., 2012). Second, 
NMDAR currents display strong voltage dependency due to a channel blockade by physiological con-
centrations of extracellular Mg2+ (Ascher & Nowak, 1988; Mayer & Westbrook, 1987). Mg2+ block is 
relieved upon strong membrane depolarization. Because of the strong voltage-dependence of the 
block, NMDARs act as coincident detectors, sensing postsynaptic depolarization at the same time as or 
shortly after release of glutamate from presynaptic terminal. This enables NMDARs to mediate synap-
tic plasticity and associative learning. Third, NMDAR channels are highly permeable to Ca2+ (Moriyoshi 
et al., 1991), which acts as a second messenger in diverse intracellular signaling pathways. Excess Ca2+ is 
also toxic to neurons, and hyperactivation of NMDARs is thus thought to contribute to a variety of 
neurodegenerative disorders. Fourth, NMDARs display slow activation and deactivation kinetics, com-
pared to other ionotropic glutamate receptors. Overall, these properties confer crucial roles to 
NMDARs, in particular those of coincidence detectors capable of synaptic integration and of activa-
tion of  intracellular signaling cascades.
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 Despite these commonalities, the particular subunit composition will confer variable biophysical 
and signaling properties to the different NMDAR subtypes. These properties include channel permea-
tion and gating as well as protein-protein interactions, trafficking and plasma membrane localization.
  I.4.1. Channel permeation
 Permeation properties that differ between NMDAR subtypes are their single-channel conduc-
tances, Ca2+ permeability and block by extracellular Mg2+ (Stern, Béhé, Schoepfer, & Colquhoun, 1992; 
Dingledine, Borges, Bowie, & Traynelis, 1999; Cull-Candy, Brickley, & Farrant, 2001; Table 1). 
NMDARs show a pair of conductance states, the amplitude and relative frequency of which depends 
on the GluN2 subunit integrating the channel. Receptors composed of GluN2A or GluN2B subunits 
display large conductances while receptors containing GluN2C or GluN2D subunits show smaller 
conductances. Voltage-dependent inhibition by extracellular Mg2+ of GluN1/GluN2A or GluN1/
GluN2B responses is at least four-fold stronger than inhibition of GluN1/GluN2C or GluN1/
GluN2D responses at all voltages tested (Kuner & Schoepfer, 1996; Qian, Buller, & Johnson, 2005); 
(Qian & Johnson, 2006). Ca2+ permeability also differs: it is higher in GluN2A- and GluN2B-
containing receptors than in GluN2C- and GluN2D-containing receptors (Burnashev, Zhou, Neher, & 
Sakmann, 1995; Schneggenburger, 1996).
Table 1. GluN2 subunit-specific permeation properties. Pf, fractional Ca2+ current; EC50, half maximal effective 
concentration; IC50, half  maximal inhibitory concentration; Vm, membrane potential (Paoletti, 2011).
 The structural determinants that control the conductance and permeation properties of 
NMDARs reside in the re-entrant M2 loop, which lines the inner cavity of the channel pore (Kuner, 
Wollmuth, Karlin, Seeburg, & Sakmann, 1996; Sakurada, Masu, & Nakanishi, 1993; Kuner & 
Schoepfer, 1996; Mori & Mishina, 1995). One key determinant is the identity of the residue occupying 
a functionally critical position at the apex of the M2 loop, the "QRN" site, that is an asparagine in 
GluN1 and GluN2 subunits (Burnashev et al., 1992; Mori, Masaki, Yamakura, & Mishina, 1992). The 
asparagine in the QNR site of the GluN1 and an adjacent asparagine (i.e., QRN+1 site) in GluN2 form 
a narrow constriction within the channel pore (Wollmuth, Kuner, Seeburg, & Sakmann, 1996) and in-
fluences single-channel conductance, Ca2+ permeability (Burnashev et al., 1992) as well as Mg2+ sensi-
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tivity (Burnashev et al., 1992; Mori et al., 1992). In addition to residues at or near the QNR sites, a glu-
tamine residue located six positions C-terminal to the QNR site in GluN2A regulates Ca2+ permeability 
(Vissel, Krupp, Heinemann, & Westbrook, 2002), suggesting that this position may underlie GluN2 
subunit-specific differences in Ca2+ permeability. A highly conserved GluN2B tryptophan residue 
(W607) in the M2 loop also has been proposed to contribute to the narrow constriction (Williams et al., 
1998). Occupancy of permeant ion-binding sites in the external and internal cavities of the channel 
pore by Na+ or K+ alters the association and dissociation rates of Mg2+ from its blocking site (Qian, 
Antonov, & Johnson, 2002). The nature of these ion-binding sites differs between GluN2 subunits and 
hence, may underlie some GluN2-specific effects on Mg2+ block (Qian & Johnson, 2006; Kuner & 
Schoepfer, 1996). Moreover, the rates for Mg2+ unblock and reblock depend on the GluN2 subunit; 
receptors containing GluN2C or GluN2D unblock more rapidly than those containing GluN2A or 
GluN2B (Clarke & Johnson, 2006). Although considerably less attention has been dedicated to the 
GluN3 subunits, it is known that they have unique properties. For example unlike GluN2 subunits, 
GluN3 binds to glycine and not to glutamate. Therefore, NMDARs containing exclusively GluN1/
GluN3 subunits can as excitatory glycine receptors, which are impermeable to Ca2+. Tri-heteromers 
containing GluN2 and GluN3 subunits, however, are sensitive to glutamate, but they show a decrease 
in open probability, Ca2+ permeability, and Mg2+ sensitivity in comparison with GluN1/GluN2 
NMDARs (Henson et al., 2010). Insensivity to Mg2+ may explain why GluN3- and GluN2C-containing 
NMDARs expressed on oligodendrocytes (Piña-Crespo et al., 2010; Burzomato, Frugier, Pérez-Otaño, 
Kittler, & Attwell, 2010) can be active while the membrane (myelin sheath) on which they reside expe-
riences little depolarization.
  I.4.2 Channel gating
 Depending on their subunit composition, NMDAR subtypes display distinct gating properties, 
including sensitivity to agonists, activation and deactivation kinetics and channel mean open time and 
maximal open probability. Although the GluN1 glycine/D-serine binding site is common to all 
NMDAR subtypes, the identity of the GluN2 subunit influences their affinity for D-serine versus 
glycine (Matsui et al., 1995; Madry et al., 2007; Priestley et al., 1995). GluN1/GluN2B subtypes bind 
glycine with a 10-fold better affinity than do GluN1/GluN2A subtypes, and exhibit a stronger affinity 
for glycine than for D-serine (EC50, concentration producing half-maximal response, being ~0.057 ver-
sus 0.15 µM, respectively) (Priestley et al., 1995; Madry et al., 2007). On the contrary, GluN2A-
containing NMDARs exhibit a slightly stronger affinity for D-serine over glycine (EC50 ~0.22 versus 
0.53 µM, respectively) (Priestley et al., 1995; Matsui et al., 1995). Also, affinity for glutamate, measured 
as the steady-state EC50 varies with the GluN2 subunits in the following order: GluN2A < GluN2B ~ 
GluN2C < GluN2D.
 A similar ranking of subunits is found for measurements of glutamate deactivation kinetics, i.e. 
The time course of the macroscopic current decay following a brief pulse of glutamate (Monyer et al., 
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1994; Vicini et al., 1998; Yuan, Hansen, Vance, Ogden, & Traynelis, 2009; Fig. 5). The time course of 
decay of NMDAR currents is crucial for synaptic transmission because it governs the duration of the 
slow, NMDAR-mediated component of excitatory postsynaptic currents (EPSCs) (Lester et al., 1990). 
GluN1/GluN2A receptors have the fastest decay with a time constant of tens of milliseconds. 
GluN1/GluN2D receptors are the slowest (in the order of seconds) (Wyllie, Béhé, & Colquhoun, 
1998). The molecular determinants responsible for the difference in glutamate sensitivity and deactiva-
tion kinetics between GluN1/GluN2 receptor subtypes are yet to be identified.
Fig. 5: Decay of NMDAR currents. Macroscopic recombinant NMDARs in response to glutamate, illustrating GluN2 
subunit-dependent deactivation. τw, weighted deactivation time constant; higher τw signifies slower decay. (Data from 
Vicini et al., 1998; image from Paoletti et al., 2013)
τw	  ~50	  ms τw	  ~300	  ms τw	  ~280	  ms
τw	  ~1.7	  s
 The maximal open probability (P0), that is the probability of the ion channel being in an open 
state while the agonist binding sites are fully occupied, is another key gating parameter that varies be-
tween NMDAR subtypes. P0 is high for GluN1/GluN2A receptors, intermediate for GluN1/GluN2B 
receptors and very low for GluN1/GluN2C and GluN1/GluN2D receptors (Wyllie et al., 1998; G. Q. 
Chen, Cui, Mayer, & Gouaux, 1999; Erreger, Dravid, Banke, Wyllie, & Traynelis, 2005; Dravid, Prakash, 
& Traynelis, 2008). Moreover, the channel mean open time, that reflects the stability of the open state 
of a channel, is higher for GluN2A- or GluN2B-containing channels than for GluN2C- or GluN2D-
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containing ones. The higher open probability and faster deactivation at single-channel level result in the 
faster rise and decay times observed macroscopically for GluN2A-containing NMDARs in response to 
glutamate release compared to GluN2B-containing ones. Although GluN1/GluN2B channels may 
have lower peak currents, they carry about two-fold more charge for a single synaptic event than 
GluN1/GluN2A channels because the deactivation of GluN2B channels is slow enough to compen-
sate for their low open probability (Erreger et al., 2005). Unfortunately, little is known about gating 
properties of tri-heteromeric receptors containing more than on type of GluN2 subunit or a GluN2 
subunit and a GluN3 subunit. To date, our understanding of how NMDAR channel properties are de-
fined by the GluN2 subunit composition is mostly based on studies of recombinant receptors. Further 
studies on native NMDARs in an intact neuronal preparation are needed to confirm these conclusions. 
Recently, an elegant study using conditional deletion of GluN2A and GluN2B in single neurons in the 
hippocampal CA1 region of mice determined the biophysical properties of pure di-heterometric 
NMDARs (GluN1/GluN2A or GluN1/GluN2B) (Gray et al., 2011). The subtype dependence of cur-
rent kinetics and open probability of these native NMDARs was similar to the findings in heterologous 
systems.
  I.4.3. Synaptic localization
 There is a long-standing paradox that NMDA (N-methyl-d-aspartate) receptors (NMDARs) can 
both promote neuronal health and kill neurons. NMDAR-induced responses depend on the receptor 
localization: stimulation of synaptic NMDARs, acting primarily through nuclear Ca2+ signaling, leads to 
the build-up of a neuroprotective ‘shield’, whereas stimulation of extrasynaptic NMDARs promotes 
cell death. These differences result from the activation of distinct genomic programs and from oppos-
ing actions on intracellular signaling pathways. Perturbations in the balance between synaptic and extra-
synaptic NMDAR activity contribute to neuronal dysfunction in acute ischemia and Huntington’s dis-
ease, and could be a common theme in the aetiology of neurodegenerative diseases (Hardingham & 
Bading, 2010; Fig. 6).
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Fig. 6: χ-shaped model of NMDAR-dependent excitotoxicity. The schematic illustrates the opposing effects of 
increasing synaptic and extrasynaptic NMDAR (N-methyl-d-aspartate receptor) activity on neuronal survival and 
resistance to trauma. Hypoactivity of synaptic NMDARs is harmful to neurons. Enhancing synaptic NMDAR activity 
triggers multiple neuroprotective pathways and this promotes neuronal survival. Low  levels of activation of extrasynaptic 
NMDARs have no effects on neuronal survival but increasing the level of extrasynaptic NMDAR activity activates cell 
death pathways and exacerbates certain neurodegenerative processes, thus reducing neuronal survival ({Hardingham & 
Badding, 2010).
 At the neuronal surface and at the synapses, NMDAR distribution is not homogenous and highly 
depends on their GluN2 subunit composition. Growing evidence suggests that GluN2A-containing 
NMDARs occupy the central portion of the mature synapse while GluN2B-containing NMDARs are 
preferentially targeted to perisynaptic and extrasynaptic sites (Stocca & Vicini, 1998; J. H. Li et al., 1998; 
Tovar & Westbrook, 1999; Groc et al., 2006). For instance, in the visual cortex, NMDAR-EPSCs lose 
their sensitivity to GluN2B-specific antagonists by P7, but the extrasynaptic receptors are still blocked, 
suggesting that GluN1/GluN2B receptors are restricted to extrasynaptic sites beyond a certain stage of 
development (Stocca & Vicini, 1998). Moreover, electrophysiological characterization in acute hippo-
campal slices obtained from adult rats indicates that synaptic receptors at CA3-CA1 synapses are pre-
dominantly composed of GluN2A-containing NMDARs (Papouin et al., 2012). The GluN2B-
NMDARs antagonist Ro25-6981 did not affect the slope of NMDAR-field excitatory postsynaptic po-
tentials (fEPSPs) but free zinc, a highly specific allosteric inhibitor of GluN2A-NMDARs, strongly re-
duced synaptic NMDAR-fEPSPs. Further, immunocytochemical analysis revealed that GluN2B clusters 
occur both at synaptic and extrasynaptic sites in cultured cortical neurons, while GluN2A clusters are 
almost exclusively synaptic (J. H. Li et al., 1998).
 Ultrastructural studies using immunogold labeling also showed a preferential localization of the 
GluN2B subunit in the perisynaptic area and of the GluN2A subunit at the center of the synapse (Shi-
nohara et al., 2008; J. Zhang & Diamond, 2009). Investigation of surface mobility of native GluN2A 
and GluN2B subunits in cultured neurons using single-molecule and -particle approaches revealed that 
GluN2A-NMDARs are less mobile and more retained within synapses than GluN2B-NMDARs be-
cause of  differential lateral diffusion at the neuronal surface (Groc et al., 2006).
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 However, the segregation of GluN2A and GluN2B to synaptic and extrasynaptic sites is not ab-
solute, as has been shown in many studies (Mohrmann, Köhr, Hatt, Sprengel, & Gottmann, 2002; C. G. 
Thomas, Miller, & Westbrook, 2006). For instance, the sensitivity to GluN2B-specific antagonists has 
been shown to be comparable between synaptic and extrasynaptic sites (A. Z. Harris & Pettit, 2007; C. 
G. Thomas et al., 2006). It is to be noted that the synaptic content of NMDAR subtypes changes dur-
ing brain development (Kew, Richards, Mutel, & Kemp, 1998; Kirson & Yaari, 1996), sensory experi-
ence (Quinlan et al., 1999a; (Quinlan, Philpot, Huganir, & Bear, 1999b; Philpot et al., 2001) or synaptic 
plasticity (Bellone & Nicoll, 2007; Matta, Ashby, Sanz-Clemente, Roche, & Isaac, 2011). Therefore, 
some of the apparent discrepancies may be resolved when taking into account developmental and re-
gional differences in the localization of NMDAR subtypes as well as the experimental paradigms used 
for its study (Köhr, 2007).
  I.4.4. Protein-protein interactions.
 Proteins interacting with NMDAR subunits are important in determining the direction of synap-
tic plasticity as they couple NMDARs to distinct downstream signaling pathways (Kennedy, Beale, Car-
lisle, & Washburn, 2005). GluN2A and GluN2B, each with an extended C-terminus (630 and 650 
amino acids, respectively), interact with different intracellular proteins. Ca2+-calmodulin-dependent pro-
tein kinase II (CaMKII), a key mediator of long-term potentiation (LTP), binds with high affinity to 
GluN2B (A. S. Leonard, Lim, Hemsworth, Horne, & Hell, 1999; Strack & Colbran, 1998) as well as to 
the GluN2A subunit (Gardoni et al., 1998). CaMKII activation and its association to GluN2B are re-
quired for LTP induction (Lisman, Schulman, & Cline, 2002; Barria & Malinow, 2005). Other unique 
binding partners of GluN2B include Ras-guanine nucleotide-releasing factor (Ras-GRF1) (Krapivinsky 
et al., 2003) and Ras GTPase activating protein (RasGAP) (J. H. Kim, Liao, Lau, & Huganir, 1998); as-
sociations which might also affect the induction of plasticity (Zhu, Qin, Zhao, Van Aelst, & Malinow, 
2002). GluN2B binds the cytoskeletal protein α-actinin and the clathrin adaptor protein AP2 through a 
common binding site (YEKL) near the distal end of its C-terminus (Lavezzari, McCallum, Lee, & 
Roche, 2003; (Nakazawa et al., 2006). Interactions with these two proteins bidirectionally regulate the 
synaptic localization of GluN2B. On the other hand, the neuronal nitric oxide synthase, Homer and β-
catenin are synaptic proteins that bind GluN2A more effectively than GluN2B (Al-Hallaq et al., 2007), 
although these interactions seem to be direct.
 Both GluN2A and GluN2B, through PDZ-binding motifs (ESDV) in their extreme C-termini, 
interact with members of the membrane-associated guanylate kinase (MAGUK) family of synaptic 
scaffolding proteins, such as PSD-93, PSD-95, SAP97, SAP102. These interactions are involved in an-
choring NMDARs at the synapse (Kennedy, 2000), and studies suggested that differential interaction of 
each GluN2 subunit with MAGUKs might determine the distinct synaptic localization of each subtype 
(Townsend, Yoshii, Mishina, & Constantine-Paton, 2003; Sans et al., 2000). However, a recent report 
indicates that the MAGUK proteins interact with GluN1/GluN2A and GluN1/GluN2B receptors at 
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comparable levels (Al-Hallaq et al., 2007). Thus, further studies are required to understand the associa-
tion of NMDAR subunits with these scaffolding proteins and its influence on their subcellular localiza-
tion. Both GluN2A and GluN2B directly interact with flotillin-1, a lipid raft-associated protein, via 
analogous regions in their distal C-termini (Swanwick, Shapiro, Yi, Chang, & Wenthold, 2009), and this 
interaction potentially recruits NMDARs to signaling microdomains within lipid rafts.
II. Modulation of  NMDA receptor localization in neurodegenerative diseases and other disor-
ders.
 Mislocalization and abnormal trafficking of NMDAR subunits have been reported in several 
brain disorders and neurodegenerative diseases. Excessive calcium influx through NMDARs triggers 
excitotoxic cell death mediated by downstream signaling cascades (Lynch & Guttmann, 2002). The 
mode of calcium entry depends on not only the number but also the subtype of NMDARs present at 
the cell surface, given the distinct biophysical properties of the individual subunits. Furthermore, the 
excitotoxicity of NMDR activity is not only dependent on the degree of activation or specific subtype 
but also on the synaptic or extrasynaptic localization of those NMDAR subtypes (Hardingham & Bad-
ing, 2010).
 Beyond the traditional view of excitotoxic cell death, recent studies suggest that disruptions in 
NMDAR trafficking and targeting may be the culprit for NMDAR dysfunction in various neuropa-
thological conditions (C. G. Lau & Zukin, 2007). Dynamic trafficking of NMDARs to and from the 
cell surface or to and from extrasynaptic sites is a powerful mode of controlling the abundance and 
composition of surface and/or synaptic NMDARs. Thus, dysregulation of NMDAR trafficking would 
contribute to impairment of synaptic function, that may eventually result in the collapse of the synaptic 
functional unit in the absence of  excitotoxic cell death.
 In this part, examples of some neurodegenerative diseases and other disorders will be summa-
rized although more attention will be put on the modulation of NMDAR in Parkinson's disease (PD) 
and L-DOPA-Induced Dyskinesia (LID) as it was the focus of  our study.
 II.1. Ischemia and stroke
 Calcium influx through extrasynaptic NMDARS has been associated with the induction of cell 
death, while that through synaptic receptors mediates induction of synaptic plasticity and has pro-
survival effects (Hardingham, Fukunaga, & Bading, 2002). Thus, synaptic or extrasynaptic localization 
determines whether NMDAR activation prevents or promotes neurotoxicity because of coupling to 
either anti- or pro-apoptotic downstream signaling cascades, respectively. Perturbations in the balance 
between synaptic and extrasynaptic NMDAR activity has been implicated in ischemic stroke. For in-
stance, enhanced activity of extrasynaptic NMDARs has been shown to contribute to the acute neu-
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ronal dysfunction during an ischemic episode following extracellular accumulation of glutamate (Tu et 
al., 2010).
 II.2. Alcohol abuse
 Regulation of NMDAR trafficking by ethanol underlies the plastic modifications of neural cir-
cuitry associated with alcohol abuse. In the hippocampus, acute ethanol administration promotes selec-
tive internalization of GluN2A through H-Ras activation and inhibition of Src, thereby changing the 
synaptic NMDAR complement from a mixture of GluN2A- and GluN2B-containing receptors to ex-
clusively GluN2B ones (Suvarna et al., 2005). On the other hand, chronic exposure to ethanol has been 
shown to induce synaptic incorporation of NMDARs without affecting extrasynaptic (Carpenter-
Hyland, Woodward, & Chandler, 2004).
 II.3. Alzheimer's disease
  Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by impair-
ments in memory and cognition. The pathogenesis of the disease is linked to abnormal production of 
β-amyloid (Aβ) peptide and formation of neurofibrillary tangles and plaques having neurotoxic effects. 
Recent studies show that elevated levels of Aβ  impair glutamatergic transmission and inhibit synaptic 
plasticity, suggesting a glutamatergic synaptic dysfunction at early stages of the disease (Selkoe, 2002). 
Mechanistically, NMDARs have been implicated in the loss of synapses in the AD brain (Shankar et al., 
2007). Discrepant results regarding alterations in NMDAR subunit expression suggest that additional 
mechanisms may be involved in the neuropathological changes observed in the susceptible brain re-
gions (Hynd, Scott, & Dodd, 2004). One such mechanism is the increased endocytosis of NMDARs 
stimulated y Aβ  in cultured cortical neurons and in transgenic mice expressing mutant amyloid precur-
sor protein (APP), the precursor of Aβ  (Snyder et al., 2005). Altered striatal enriched tyrosine phos-
phatase (STEP) activity has been associated with cognitive impairments in AD. STEP61 expression and 
activity are significantly increased in transgenic AD mice and human AD brain (Kurup et al., 2010). Al-
though STEP is normally ubiquitinated, it is not degraded efficiently due to proteosome inhibition by 
Aβ. High-affinity binding of Aβ  to α-7-nicotinic acetylcholine receptor results in increased Ca2+ influx, 
calcineurin activation and dephosphorylation and activation of STEP61. Increased STEP61 activity 
leads to Fyn inaction and reduced NMDAR exocytosis, as well as enhanced GluN2B Y1472 dephos-
phorylation and increased NMDAR internalization (Kurup et al., 2010). Thus, increased expression and 
activity of STEP61 alters synaptic glutamatergic signaling and may contribute to AD cognitive dysfunc-
tion. Also, Aβ production is enhanced by chronic extrasynaptic NMDAR activation, which is blocked 
by the NMDAR antagonist memantine (Bordji, Becerril-Ortega, Nicole, & Buisson, 2010). In summary, 
AD neuronal dysfunction involves an imbalance between synaptic and extrasynaptic NMDAR localiza-
tion and function; whereas synaptic NMDARs are depleted, extrasynaptic NMDAR-mediated signaling 
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is sustained, facilitating detrimental Aβ  synthesis and downstream pathogenesis. (Gladding & Ray-
mond, 2011).
 II.4. Huntington's disease
 Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder 
characterized by cognitive deficits, motor decline, and mood dysfunction (Harper, 1992). The disease 
involves extensive and selective cell death in GABAergic projection medium-sized spiny neurons 
(MSNs) of the neostriatum and, to a lesser extent, cell death in the cortex (Vonsattel & DiFiglia, 1998). 
The pathology is caused by an expansion of the CAG repeats in the huntingtin (htt) gene that leads to 
an expanded polyglutamine repeats in the protein (Landles & Bates, 2004). Normal htt binds to PSD-
95, resulting in the inhibition of NMDAR activity and significant attenuation of neuronal toxicity in-
duced by both NMDA and a mutated form of htt (Sun, Savanenin, Reddy, & Liu, 2001). Mutated htt 
(mhtt) has an abnormal conformation and can be cleaved to generate toxic fragments that form aggre-
gates and interfere with vital cellular processes, such as mitochondrial function, Ca2+ signaling and ho-
meostasis, gene transcription and vesicular trafficking (Zuccato, Valenza, & Cattaneo, 2010). Recent 
evidence indicates that aberrant glutamatergic transmission involving altered NMDAR activity and traf-
ficking contributes to HD neuropathology. In the YAC128 transgenic mouse model of HD, that ex-
presses mhtt with a 128-length polyglutamine expansion, striatal NMDAR activation and excitotoxicity 
is enhanced, NMDAR currents and surface expression are increased in these mice with specific in-
creases in the extrasynaptic NMDAR activity, dominated by GluN2B-containing NMDARs, due at least 
in part to enhanced NMDAR forward trafficking to the plasma membrane that contribute to the phe-
notype onset (Cepeda et al., 2001; M. M. Y. Fan, Fernandes, Zhang, Hayden, & Raymond, 2007; Fer-
nandes, Baimbridge, Church, Hayden, & Raymond, 2007; Graham et al., 2009; L. Li, Murphy, Hayden, 
& Raymond, 2004; Milnerwood & Raymond, 2007; Shehadeh et al., 2006; Zeron et al., 2002; H. Zhang 
et al., 2008). In HD transgenic models, an alteration of membrane-associated neuronal nitric oxide syn-
thase (nNOS) and a decrease in PSD-95, which link nNOS to the NMDAR was observed (Luthi-Carter 
et al., 2003; Jarabek, Yasuda, & Wolfe, 2004). Overall, NMDAR/PSD-95 complex can be considered a 
key factor contributing to excitotoxicity in preclinical models of HD, specifically striatal PSD-95 local-
ization is shifted to non-synaptic membranes, as the PSD-95/htt association decreases in the presence 
of mhtt, presumably increasing the availability of unbound PSD-95 to anchor and stabilize NMDAR 
on the surface (Sun et al., 2001; J. Fan, Cowan, Zhang, Hayden, & Raymond, 2009). It results in an en-
hanced formation of GluN2B/PSD-95 complex at non-postsynaptic density fractions (J. Fan et al., 
2009). Alterations in synaptic and extrasynaptic NMDAR localization can lead to imbalance of pro-
survival and pro-apoptotic signaling (Hardingham & Bading, 2010) and is a critical element in neuronal 
cell survival in HD (Levine, Cepeda, & André, 2010).
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 II.5. Parkinson's disease and L-DOPA-induced dyskinesia
 Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the accu-
mulation of α-synuclein inclusions (Lewy bodies) and progressive dysfunction and death of the dopa-
minergic (DA) neurons projecting from the substantia nigra to the striatum, and consequently, the de-
pletion of dopamine in the striatum (Shulman, De Jager, & Feany, 2011). The dopamine deficit can be 
mimicked in animal models by inducing nigrostriatal denervation with injections of the neurotoxin 6-
hydroxydopamine (6-OHDA) (Ungerstedt & Arbuthnott, 1970). The degeneration of the nigrostriatal 
dopaminergic pathway in PD leads to significant morphological and functional changes in the striatal 
neuronal circuitry, including overactivity of the corticostriatal glutamatergic pathway. The alteration in 
the nigrostriatal pathway results in the motor symptoms characteristic of PD as dopaminergic and glu-
tamatergic signaling interact to control motor function.
 Among the various modifications in the glutamatergic striatal synapses in PD, several studies re-
ported alterations in NMDA receptor subunit composition at the dendritic spines of medium spiny 
neurons (MSNs) (Gardoni, Ghiglieri, Luca, & Calabresi, 2010; Sgambato-Faure & Cenci, 2012; Mellone 
& Gardoni, 2013; Fig. 7). Changes in subcellular localization of NMDARs have been reported in 6-
OHDA mouse models of PD. The amount of GluN1 and GluN2B, but not GluN2A, in membrane 
fractions decreased in the 6-OHDA lesioned striatum relative to the unlesioned striatum (Dunah et al., 
2000). Further studies indicated that alterations in NMDAR subunit composition at synapse correlated 
with the reduction of corticostriatal synaptic plasticity (Picconi et al., 2003; Picconi et al., 2004; Gar-
doni et al., 2006). In particular, GluN2B-containing NMDAR are specifically reduced in synaptic frac-
tion purified from parkisonian rats (Gardoni et al., 2006). Similar results were found in a monkey model 
of PD, the MPTP-treated macaques. Interestingly, alterations of NMDAR subunit localization at syn-
apse are associated with a decreased interaction with PSD-95 (Picconi et al., 2004; Gardoni et al., 2006). 
Furthermore, other studies reported that experimental parkisonism in rats is related to a decreased syn-
aptic membrane localization and increased vesicular localization of members of the PSD-MAGUK 
family (Nash, Johnston, Collingridge, Garner, & Brotchie, 2005) which may account for the observed 
dysregulation of  NMDAR at the synapse (Mellone & Gardoni, 2013).
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Fig. 7. Alterations of NMDA receptors at striatal spines in Parkinson's disease. At the striatal level, glutamatergic 
and dopaminergic inputs converge to the spines of medium spiny neurons where it is for the output responsible for 
motor skills among many. In PD, the dopaminergic afferents are lost inducing an increase un glutamate release, a 
redistribution of  GluN2B to extrasynaptic sites and an increase of  GluN2A at the synapse.
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 An important feature in PD is the onset of dyskinetic movements as a consequence of chronic 
L-DOPA treatment. L-DOPA-induced dyskinesias (LID) represent the main side effect of the thera-
peutic strategy clinically used in PD (Calabresi, Di Filippo, Ghiglieri, Tambasco, & Picconi, 2010). Al-
though its discovery constitutes a major milestone in the modern neuropharmacology (Birkmayer & 
Hornykiewicz, 1961; Mercuri & Bernardi, 2005), the beneficial "honeymoon" phase of the treatment is 
followed by the appearance of motor fluctuations in the drug efficacy ("on-off" state) and dyskinesias 
(Calabresi et al., 2010; Cotzias, Papavasiliou, & Gellene, 1969). Among the numerous players involved 
in the onset of dyskinesia, excessive striatal glutamatergic transmission exerts a central role (Gardoni et 
al., 2010; Sgambato-Faure & Cenci, 2012). After chronic L-DOPA treatment the glutamatergic signaling 
from cortex to the striatum undergoes further adaptive changes, resulting in an abnormal NMDAR 
composition and function at dendritic spines of striatal medium spiny neurons (Gardoni et al., 2006). 
L-DOPA-treated dyskinetic rats have significantly higher levels of GluN2A subunit, while GluN2B is 
reduced at the postsynaptic compartment and redistributed to extrasynaptic membranes (Gardoni et al., 
2006). Similar data was found in dyskinetic MPTP-monkeys as well as in PD patients treated with L-
DOPA (Gardoni et al., not published; Fig. 8). These events are paralleled by modifications in the asso-
ciation of GluN2B subunit with members of the PSD-MAGUKs family (Gardoni et al., 2006). Nota-
bly, it has been demonstrated that these molecular alterations are strictly correlated to abnormal synap-
tic plasticity and motor behavior in L-DOPA-treated dyskinetic rats (Picconi et al., 2003). Treatment of 
non-dyskinetic animals with a cell-permeable peptide (TAT-GluN2B9c), able to affect the synaptic lo-
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calization of GluN2B-containing NMDAR by interfering with its binding to PSD-MAGUK proteins, 
caused a worsening of motor symptoms with the appearance of dyskinetic behaviors (Gardoni et al., 
2006). Overall, these data further support the idea that molecular disturbance of the glutamatergic syn-
apse, initially caused by dopamine denervation, create a pathological substrate that may have causal role 
in the development of  dyskinesia (Gardoni et al., 2010; Mellone & Gardoni, 2013).Composi'o )of)the)NMDA)receptor)in)de dri'c)spines)of)MSNs)
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Fig. 8: NMDAR composition at the synapse in LID. Gardoni et al. Have demonstrated that there is a increase of 
GluN2A/GluN2B ratio in the 6-OHDA lesioned rat model of LID compared to the dyskinetic conterpart (Gardoni et al., 
2006), the MPTP monkey model of LID but also in PD patients treated with L-DOPA compared to aged-matched 
healthy subjects (Gardoni et al., not published).
 The efficacy of NMDAR antagonists in blocking the onset of dyskinesia without influencing the 
beneficial effects of the treatment on parkinsonian symptoms was examined in animal models of PD 
(Nash et al., 2000; Löschmann et al., 2004; Hadj Tahar et al., 2004; Wessell et al., 2004). Overall, there is 
a general agreement that NMDAR blockade attenuates parkinsonian motor symptoms and improves 
dopaminergic therapy. However, classical NMDA agents are not well tolerated by primates because of 
numerous side effects. Therefore, recent research has focused on low-affinity or subunit-specific 
NMDAR antagonists in order to ameliorate parkinsonian symptoms in absence of major adverse ef-
fects (Mellone & Gardoni, 2013).
 Amantadine is a low-affinity, non-competitive antagonist of NMDAR (Kornhuber, Bormann, 
Hübers, Rusche, & Riederer, 1991). Several studies demonstrated that amantadine exhibits anti-
dyskinetic activity even if the beneficial effects is attenuated after a few months (Verhagen Metman et 
al., 1998; Luginger, Wenning, Bösch, & Poewe, 2000; Snow, Macdonald, Mcauley, & Wallis, 2000; A. 
Thomas et al., 2004; da Silva-Júnior, Braga-Neto, Sueli Monte, & de Bruin, 2005). However, a random-
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ized, placebo-controlled, parallel-group study recently demonstrated a long-term (>1 year) anti-
dyskinetic effect of amantadine in a limited cohort of patients (Wolf et al., 2010). Furthermore, a meta-
analysis based on 11 randomized, placebo-controlled clinical trials confirmed at least the short-term 
benefits of  amantadine therapy in the treatment of  dyskinesia (Elahi, Phielipp, & Chen, 2012).
 GluN2B-selective antagonist ifenprodil, together with its derivatives, seemed well suited for 
treatment of PD as well as LID as they induced reduced parkinsonian symptoms in different animal 
models (Steece-Collier, Chambers, Jaw-Tsai, Menniti, & Greenamyre, 2000; Nash et al., 2004; Hadj Ta-
har et al., 2004; Morissette et al., 2006). However, contradictory results have been provided by recent 
studies on the the effects of GluN2B-selective antagonists on the onset of LID in experimental models 
of parkinsonism (Rylander et al., 2009; Nash et al., 2000; Wessell et al., 2004) as well as dose-related 
dissociation and detrimental side effects like amnesia in randomized, double-blind, placebo-controlled 
clinical trial (Nutt et al., 2008).
 While there is an increasing research on GluN2B-specific compounds, few studies have been per-
formed on GluN2A-selective agents. A recent work, which applied a cell-permeable peptide disrupting 
GluN2A/PSD-MAGUKs interaction, demonstrated that a decrease in synaptic GluN2A-containing 
NMDA receptors induces a significant reduction in the onset of LID (Gardoni et al., 2011) in parkin-
sonian rats (Mellone & Gardoni, 2013).
III. GluN2A/B trafficking and targeting to synapses
 It is believed that the protein-protein interactions in the cytoplasmic C-terminus and the extracel-
lular N-terminus of the receptor determine the precise localization of GluN2 subunits. For example, 
the PDZ binding motif at the extreme C-terminus of both GluN2A and GluN2B subunits binds to 
the second PDZ domain of MAGUK proteins, which act as scaffolding proteins. Members of this 
family (PSD-93, PSD-95, SAP97 and SAP102) show differential subcellular localization, with PSD-95 
predominantly expressed at the postsynaptic density and SAP102 being distributed more evenly be-
tween synaptic and extrasynaptic sites. In addition, a preferential association of GluN2A/PSD-95 and 
GluN2B/SAP102 has been reported (Sans et al., 2000; although see Al-Hallaq et al., 2007). Therefore, a 
working model proposes that binding of GluN2 subunits to different MAGUK proteins controls 
NMDAR localization. Current data support this scenario for GluN2B because the disruption of the 
GluN2B PDZ binding domain results in a lost of synaptic GluN2B as demonstrated by electrophysio-
logical and confocal imaging approaches (H. J. Chung, Huang, Lau, & Huganir, 2004; Prybylowski et 
al., 2005). In contrast, the literature for GluN2A is less consistent because GluN2A expressing a point 
mutation disrupting its PDZ binding domain has similar NMDA-mEPSCs compared to GluN2A wild-
type in transfected cerebellar granule cells (Prybylowski et al., 2005, but see Barria & Malinow, 2002). 
However, a genetically modified mouse line expressing GluN2A lacking the C-terminus (GluN2A∆C/
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∆C) (Sprengel et al., 1998) shows a reduced synaptic GluN2A expression, as revealed by biochemical 
subcellular fractionation and electron microscopy (Steigerwald et al., 2000). Consistently, GluN2A∆C/∆C 
mice display slower NMDAR kinetics, indicating a decrease in synaptic GluN2A (Steigerwald et al., 
2000). A possible explanation for these data is the existence of additional protein binding domains, 
other than the PDZ binding, in the GluN2A C-terminus that act to stabilize the receptor at synaptic 
sites. Recent reports identifying PDZ-independent binding sites between GluN2 and MAGUKs sup-
port this model (B.-S. Chen, Thomas, Sanz-Clemente, & Roche, 2011; Cousins, Kenny, & Stephenson, 
2009). The extracellular domain of NMDARs also plays a role in controlling their subcellular localiza-
tion via interaction with postsynaptic proteins such as the activated EphB receptor (Dalva et al., 2000) 
and with components of the extracellular matrix such as reelin (Groc et al., 2007). Other proteins are 
likely to modulate NMDAR localization via indirect processes, including neuroligins or integrins (Jung 
et al., 2010).
The cytoplasmic C-tails of GluN2A and GluN2B contain distinct motifs that control their trafficking 
(Fig. 9). Evidence supports a model in which GluN2B is more mobile than GluN2A, and it is subject to 
regulated lateral diffusion, endocytosis, and recycling. With two different approaches, it  has been dem-
onstrated that NMDARs move in and out of synapses and that GluN2B-containing NMDARs have a 
much higher (250-fold) surface mobility (Tovar & Westbrook, 2002; Groc et al., 2006). A possible mo-
lecular explanation of these data emerges with a report showing that GluN2B is phosphorylated by 
casein kinase 2 (CK2) within its PDZ-binding domain, which disrupts the association with scaffolding 
proteins, whereas GluN2A is not (Sanz-Clemente, Matta, Isaac, & Roche, 2010). The phosphorylation 
of the PDZ ligand domain, however, is NMDAR-activity dependent, whereas the coefficient of diffu-
sion for GluN2B is not modified by synaptic activity. Also, GluN2B shows a higher ratio of endocyto-
sis than GluN2A in adult neurons (Lavezzari, McCallum, Dewey, & Roche, 2004). Another important 
difference in GluN2 subunit trafficking is postendocytic sorting. Whereas GluN2B is sorted to recy-
cling endosomes (Rab11-positive) and reinserted into the plasma membrane, GluN2A colocalizes bet-
ter with Rab9 in late endosomes following endocytosis and is subjected to lysosomal degradation 
(Lavezzari et al., 2004; Tang, Badger, Roche, & Roche, 2010).
 GluN2A and GluN2B are subject to differential regulation by several posttranslational mecha-
nisms, including palmitoylation and nitrosylation. However, the best characterized example is the 
modulation of NMDARs by phosphorylation (B.-S. Chen & Roche, 2007; Fig. 9). For example, it has 
been shown that the phosphorylation of the GluN2A C-terminus by cyclin-dependent kinase 5 (cdk5) 
increases NMDAR currents and cdk5 inhibition has protective effects against ischemic insults (J. Wang, 
Liu, Fu, Wang, & Lu, 2003). However, no cdk5-mediated phosphorylation has been reported so far for 
GluN2B. Conversely, CK2 and calcium- and calmodulin-dependent kinase II (CaMKII) phosphorylate 
GluN2B on S1480 (within its PDZ binding domain) and S1303 (within the CaMKII binding site), re-
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spectively, but not GluN2A (Omkumar, Kiely, Rosenstein, Min, & Kennedy, 1996; Sanz-Clemente et al., 
2010). It should be noted, however, that S1291 on GluN2A and S1096 on GluN2C (analogous to 
S1303 on GluN2B) are phosphorylated by PKC and PKB, respectively (B.-S. Chen & Roche, 2009; M. 
L. Jones & Leonard, 2005). Other kinases, such as PKA, PKC, and several protein tyrosine kinases (Fyn 
and Src), phosphorylate both GluN2A and GluN2B subunits, although the precise residues and the 
consequences of  their phosphorylation also differ.
Fig. 9: GluN2A and GluN2B intracellular C-terminal tail.  The GluN2A and GluN2B C-termini contain distinct 
regulatory motifs, phosphorylation sites, and protein-protein interaction domains (Sanz-Clemente, Nicoll & Roche, 2012).
	
 As discussed above, the interaction of GluN2 subunits with MAGUKs and other synaptic pro-
teins defines their differential subcellular localization. Similarly, many other parameters are determined 
by their distinct protein-protein interactions, including trafficking regulation and activation of intracel-
lular pathways. One of the classic examples is the binding of CaMKII to NMDARs. It has been re-
ported that CaMKII binds to GluN2A in vitro, but this interaction is much weaker than the well-
documented association between CaMKII and GluN2B (Bayer, De Koninck, Leonard, Hell, & Schul-
man, 2001). Calcium entry through NMDARs activates CaMKII that can then bind to GluN2B (resi-
dues 1290 - 1310). This CaMKII-GluN2B association is regulated by the CaMKII/PKC phosphoryla-
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tion of S1303 within the CaMKII binding site (Raveendran et al., 2009). The presence of CaMKII 
bound to GluN2B at synaptic sites is believed to be an important requirement for the maintenance of 
LTP, since disrupting this interaction reverses the potentiation (Sanhueza et al., 2011).
 In the end, the proteins and mechanisms involved in the targeting to the synapse are much more 
studied and understood concerning the GluN2B subunit of NMDAR unfortunately they still remains a 
lot of questions concerning the GluN2A subunit. In fact, compared to GluN2B C-terminal tail, there is 
very informations on proteins interacting with the C-terminal tail of GluN2A. Based on these consid-
erations, our lab has concentrated its focus in studying the modulation of GluN2A at synapses starting 
from the identification of new interactors of the C-terminal tail of GluN2A involved in its targeting or 
stabilization at synaptic sites. Consequently, a yeast two-hybrid screening has been performed using as 
bait the intracellular C-terminal sequence of GluN2A without the PDZ-binding sequence (aa 831 to aa 
1461) and 16 positive clones were found among which was a Rab-binding protein involved in endocy-
tosis and calcium-dependent vesicle exocytosis, Rabphilin3A.
IV. Rabphilin3A
 Rabphilin3A (Rph3A) was first identified as a vesicle-associated protein involved in the vesicular 
trafficking machinery. Rph3A was studied as a binding partner of GTP-bound Rab3A (Shirataki et al., 
1992; Shirataki et al., 1994), a member of the Rab family of GTPases implicated in vesicle docking/
fusion reactions in many systems (Simons & Zerial, 1993; Takai, Sasaki, Shirataki, & Nakanishi, 1996). 
In mice, Rph3A is a protein of 681 aa and has two functionally different domains: the N-terminal 
Rab3A-binding domain (1–179 aa) and the C-terminal two C2-like domains (C2A [380–503 aa] and 
C2B [540–672 aa] domains) interacting with Ca2+ and phospholipids (Yamaguchi et al., 1993; Fukuda, 
Kanno, & Yamamoto, 2004; Fig. 10). The NH2-terminal half of Rabphilin-3A binds to the cytoskeletal 
protein, α-actinin, and enhances its ability to bundle actin filaments (Kato et al., 1996) and the other 
half binds the GTP-bound form of Rab3A (Yamaguchi et al., 1993), maintaining Rab3A in this state by 
preventing a GTPase-activating protein from catalyzing GTP hydrolysis by Rab3A (Kishida et al., 
1993). At least two Rab3s bind to Rabphilin: the abundant Rab3A and the less abundant Rab3C (C. Li 
et al., 1994), but Rab27 has also been shown to bind Rph3A (Fukuda, 2005). The central domain of 
Rph3A is phosphorylated, as a function of stimulation, by Ca2+-calmodulin dependent protein kinase 
II (CAMKII) and by cAMP-dependent protein kinase (PKA) (Fykse, Li, & Südhof, 1995; Lonart & 
Südhof, 1998). Phosphorylation is regulated in a brain region-specific manner. The C2-like domains are 
homologous to the C2 domains of Synaptotagmin I, a calcium sensor that triggers vesicle fusion (De-
Bello, Betz, & Augustine, 1993; Südhof, 1995), and contain the residues that mediate Ca2+ binding in 
synaptotagmins (Südhof & Rizo, 1996). Recent nuclear magnetic resonance experiments confirmed 
that Ca2+ binds to Rabphilin with a relatively high affinity (Ubach, García, Nittler, Südhof, & Rizo, 
1999). Thus, rabphilin is a bona fide Ca2+-binding protein. Although Rab3A is found in all the cells 
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with a Ca2+-regulated secretion pathway, rabphilin3A is expressed only in neurons and neuron-like cells, 
such as adrenal chromaffin cells and PC12 cells (Mizoguchi et al., 1994; C. Li et al., 1994). In addition, 
the C2 domains of Rph3A bind to the cytoskeletal protein ß-adducin (Miyazaki et al., 1994), which 
functions in the assembly of spectrin–actin complexes at the plasma membrane (Hughes & Bennett, 
1995), as well as CASK (calcium/calmodulin-dependent serine protein kinase), a PDZ-containing pro-
tein of the MAGUK family (Y. Zhang, Luan, Liu, & Hu, 2001). Moreover, the C2B domain of Rph3A 
has been shown to bind SNAP-25, a member of the SNARE (soluble N-ethylmaleimide-sensitive fac-
tor attachment protein receptor) proteins, fundamental fusion machinery of vesicle exocytosis (Tsuboi 
& Fukuda, 2005). Although Rph3A is associated with synaptic vesicles (Shirataki et al., 1994; C. Li et al., 
1994), the protein lacks a membrane-spanning region. Instead, Rph3A is thought to associate with syn-
aptic vesicles by binding to another vesicular protein whose identity is not yet clear (Shirataki et al., 
1994; McKiernan, Stabila, & Macara, 1996; Stahl, Chou, Li, Südhof, & Jahn, 1996).
Fig. 10: Schematic of Rabphilin3A domains. Rph3A has a Rab binding domain (RBD) at its N-terminus, two C2 
domains (C2A and C2B), and the last 4 amino acids (VSSD) resemble a putative PDZ-binding site.
 The biochemical properties of Rph3A, in particular its ability to bind calcium, Rab3A, and the 
cytoskeleton, make it a prospective participant in synaptic vesicle trafficking (Südhof, 1997). Burns et al. 
have examined the function of this protein in the synaptic vesicle cycle showing that Rph3A regulates 
both exo- and endocytosis, (Burns, Sasaki, Takai, & Augustine, 1998). Rph3A's implication in endocyto-
sis was recently confirmed with the discovery of the interaction between Rph3A and 
Phosphatidylinositol-4,5-bisphosphate (PIP2), a key player in the neurotransmitter release process 
(Montaville et al., 2008). PIP2 represents <1% of the lipids in the plasma membrane and forms micro-
domains to regulate several signaling events (Osborne, Wen, & Meunier, 2006). More specifically, PIP2 
is involved in different stages of the neurotransmitter release process: it is required for clathrin-
mediated endocytosis (Haucke, 2005), for specific stages of exocytosis, and synaptic vesicle trafficking 
(Osborne et al., 2006).
 Rph3A is, so far, the only known C2 domain tandem containing protein where both C2 domains 
bind PIP2 (S. H. Chung et al., 1998). Montaville, P. et al., (2008) investigated the interactions of the two 
C2 domains with the PIP2 headgroup IP3 (inositol-1,4,5-trisphosphate) by NMR, that showed a well-
defined binding site on the concave surface of each domain. The binding models of both C2 domains 
of Rph3A to the IP3 differ in affinity as well as in Ca2+ dependency. The binding of IP3 to the C2A 
domain is strongly enhanced by Ca2+. Reciprocally, the binding of IP3 increases the apparent Ca2+-
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binding affinity of the C2A domain in agreement with a Target-Activated Messenger Affinity (TAMA) 
mechanism. The C2B domain binds IP3 in a Ca2+-independent fashion with low affinity. These different 
PIP2 headgroup recognition modes suggest that PIP2 is a target of the C2A domain of Rph3A while 
this phospholipid is an effector of  the C2B domain (Montaville et al., 2008).
 A further confirmation of a putative Rph3A's implication in endocytosis comes from recent 
studies showing that Rph-3A is one of the binding partners of BR-MyoVa (Brozzi et al., 2012). The 
brain-spliced isoform of Myosin Va (BR-MyoVa) plays an important role in the transport of dense core 
secretory granules (SGs) to the plasma membrane in hormone and neuropeptide-producing cells. 
Activity-dependent secretion of hormones and neuropeptides is critical for the execution of various 
endocrine functions, neurotransmission and neuronal plasticity (Park & Loh, 2008). Despite the diverse 
functions of these cells, they share some degree of similarities in the transport of their SGs which in-
volves microtubules (Rudolf, Salm, Rustom, & Gerdes, 2001; Varadi, Ainscow, Allan, & Rutter, 2002) 
and cortical actin filaments (Steyer & Almers, 1999). The active transport along actin filaments is driven 
by the motor protein myosin Va (MyoVa) (Rosé et al., 2003; Rudolf et al., 2003; Varadi, Tsuboi, & Rut-
ter, 2005). The SGs are transported from the cell center to the cell cortex primarily by the microtubule-
based motor protein conventional kinesin (Varadi et al., 2002; Varadi, Tsuboi, Johnson-Cadwell, Allan, 
& Rutter, 2003). The short-range movements in the cortical regions of the cell that carry SGs over the 
last few hundred nanometers to the cell surface involve myosin Va (MyoVa) (Varadi et al., 2005; Ivars-
son, Jing, Waselle, Regazzi, & Renström, 2005). Current studies identified novel protein-complexes that 
bind BR-MyoVa to SGs, like Rph3A that enhanced their interaction when secretion is activated (Brozzi 
et al., 2012). These findings were rather unexpected because this was the first time that direct interac-
tion between these C2 domain–containing proteins and MyoVa was demonstrated. The inhibition of its 
(and the other proteins) interaction with MyoVa nearly completely abolishes stimulated secretion. Inter-
estingly, in rat hippocampus, myosin Va regulates also the insertion of AMPA receptors (AMPARs) into 
spines during synaptic plasticity (Correia et al., 2008). Myosin Va associates with AMPARs through its 
cargo binding domain. This interaction was enhanced by active, GTP-bound Rab11, which is also 
transported by the motor protein. In particular, Myosin Va mediated the CaMKII-triggered transloca-
tion of GluA1 receptors from the dendritic shaft into spines. In summary, Myosin Va catalyzes the di-
rectional transport of  AMPARs into dendritic spines during activity-dependent synaptic plasticity.
 Mice that lack Rph3A are viable and fertile without obvious physiological impairments. Moreo-
ver, no abnormalities in synaptic transmission or plasticity were observed; notably, synaptic properties 
that are impaired in rab3A knock-out mice were unchanged in Rph3A knock-out mice. Furthermore, 
Rph3A is endowed with the properties of a Rab3 effector but is not essential for the regulatory func-
tions of  Rab3 in synaptic transmission (Schlüter et al., 1999).
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 Overall, all these results indicate that Rph3A regulates synaptic vesicle traffic and appears to do 
so at distinct stages of both the exocytotic and endocytotic pathways. Thus, even if a large amount of 
information on Rabphilin is available, there is no consensus on the precise role of Rph3A in the pre-
synaptic terminal. Finally, Rph3A interaction with Myosin Va put forward also a possible role for 
Rph3A in regulating receptor trafficking within the postsynaptic terminal.
V. Modulation of  Rph3A in CNS disorders
 Schlüter et al., (1999) therefore suggested that it is plausible that Rph3A may have no fundamen-
tal role in the execution or regulation of neurotransmitter release under normal conditions but could 
play a specialized role under, as yet unidentified, possibly more "extreme" physiological conditions; this 
hypothesis was partially confirmed when Rph3A has been shown to be involved in Huntington's Dis-
ease (Smith, Petersén, Bates, Brundin, & Li, 2005, Smith et al., 2007). Rph3A was found to be depleted 
from synapses throughout the brain in the R6/1 transgenic mouse model of HD (Smith et al., 2005). 
The depletion of Rabphilin-3A started at an age when weight loss, motor dysfunction, and cognitive 
deficits begin (Mangiarini et al., 1996), gradually became more pronounced, and was not apparent be-
fore there were clearly overt motor symptoms. The reduction of Rph3A was not due to recruitment 
into protein aggregates, since there was no colocalization of Rph3A and huntingtin aggregates but 
could be due to changes at both the transcriptional and post-translational levels. Mutant huntingtin can 
interrupt normal transcription (J.-Y. Li, Plomann, & Brundin, 2003; Sugars & Rubinsztein, 2003) and 
could be involved in causing the reduction in Rph3A mRNA in the cortex of R6/1 mice (Smith et al., 
2005). Using in situ hybridization, it was demonstrated that Rph3A mRNA expression was substantially 
reduced in the R6/1 mouse cortex compared to wild-type mice. This is interesting especially because 
changes in the corticostriatal pathway has been suggested to play an important role in the pathogenesis 
of HD and dysfunctional release of neurotransmitter at this level, such as glutamate, may also cause 
excitotoxicity (as presented earlier in II.4. Huntington's disease). These results indicate that a decrease in 
mRNA levels underlie the depletion of protein levels of Rph3A and this reduction may be involved in 
causing impaired synaptic transmission in R6/1 mice that contributes to the development of HD-like 
symptoms in R6/1 mice (Smith et al., 2005).
 A recent study found specific reductions of Rph3A immunoreactivity in AD patients compared 
with aged controls. Rph3A loss correlated with dementia severity, cholinergic deafferentation, and in-
creased βamyloid (Aβ) concentrations. Furthermore, RPH3A expression is selectively downregulated in 
cultured neurons treated with Aβ  peptides. This data suggest that presynaptic SNARE dysfunction 
forms part of  the synaptopathology of  AD (Tan et al., 2013).
 Subsequent studies suggested an involvement of Rph3A in the pathological events preceding 
overt neuronal degeneration in Parkinson’s disease (PD) and α-synucleinopathy (C. Y. Chung, Koprich, 
Siddiqi, & Isacson, 2009). With a model of slow α-synucleinopathy in rat, Chung, C.Y. et al., (2009) in-
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vestigated predegenerative changes (at 4 weeks and 8 weeks) long before cell death and striatal dopa-
mine loss, aiming to identify pathogenic changes that are most likely causal to the disease, and not a by-
product of the cell death process. They demonstrated that before neuronal loss, significant changes 
occurred in levels of proteins relevant to synaptic transmission and axonal transport in the striatum. It 
was detected a decrease in levels of proteins involved in synaptic vesicle exocytosis, including Rph3A 
and syntaxin, by 2 months. Interestingly, characterization of striatal tissue at different times after α-
synuclein overexpression revealed dynamic changes in presynaptic and axonal transport related pro-
teins. For example, levels of Rph3A, KIF3A and myosin Va were elevated at 4 weeks followed by a re-
duction at 8 weeks raising the possibility that compensatory changes occurred at 4 weeks to counteract 
the effects of A53T α-synuclein overexpression. It is plausible that such compensatory mechanisms 
were overcome by 8 weeks with progression of the disease process. In contrast to the results in the 
striatum, the expression levels of most of these proteins were not altered in the Substantia Nigra (SN), 
suggesting that the decreased protein levels seen in the striatum was not a result of general reduction of 
protein production in the cell body, but most likely due to trafficking disruption. These results demon-
strate that changes in proteins relevant to synaptic transmission and axonal transport, precede α-
synuclein-mediated neuronal death, and these findings can provide ideas for antecedent biomarkers and 
presymptomatic interventions in PD (C. Y. Chung et al., 2009).
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 NMDARs are key mediators of excitatory synaptic transmission in the brain. Their subunit com-
position is determinant for several physiological functions in the brain, i.e., synaptic plasticity. On the 
other hand, there is a general agreement that modulation of NMDAR complex subunit composition 
plays a key role in mediating at least some aspects of glutamate neurotoxicity that is thought to be a 
major mechanism in several CNS disorders.
 Based on these considerations, understanding in minute details the mechanisms governing the 
localization of NMDAR subunits at synaptic sites is necessary for a complete understanding of the 
physiology and pathology of  the excitatory synapse.
 In this context, even if the literature reported extensive studies describing the differential role of 
GluN2B-containing receptors at synaptic and extrasynaptic sites and identified relevant protein part-
ners regulating their synaptic localization, much less is known for GluN2A-containing receptors.
 It is known that the GluN2A subunit binds PSD-MAGUK family members (PSD-95, SAP97 and 
SAP102) by means of a well-described interaction of GluN2A-SDV C-terminal motif with PDZ do-
mains of PSD-MAGUKs (C. G. Lau & Zukin, 2007; Gardoni, Marcello, & Di Luca, 2009). Although 
the interaction with these important scaffolding elements plays a key role in the synaptic clustering of 
GluN2A, the molecular mechanisms regulating the synaptic targeting of GluN2A-containing receptors 
are far from being understood.
 At present, there is few information about other putative proteins which could interact with the 
very long GluN2A intracellular C-tail. Based on these considerations, we decided to study the modula-
tion of the GluN2A subunit in the synapse starting from the identification of new GluN2A-interacting 
proteins. A yeast two hybrid screening performed by using GluN2A(839-1461) as bait, without the last 
3 aa (SDV) of the PDZ-binding domain, revealed 16 new putative GluN2A-interacting proteins. One 
of  them was Rabphilin3A (Rph3A).
 Rph3A is mainly known as a presynaptic protein involved in the regulation of the vesicle traffick-
ing (both in the exo- and endocytosis). In addition, it has been demonstrated that Rph3A interacts with 
the Myosin Va cargo protein, known to catalyze the transport of AMPARs into dendritic spines during 
activity-dependent synaptic plasticity. Interestingly, Rph3A involvement in CNS disorders such as 
Huntington's disease, α-synucleinopathy and possibly Parkinson's disease has been put forward.
 Overall, the main aim of this study is to investigate the subcellular distribution of Rph3A in neu-
rons, its interactions with GluN2A and with a PDZ-containing protein like PSD-95, and the role of 
these interactions in the synaptic localization of GluN2A in physiological conditions, in the hippocam-
pal glutamatergic synapse, and in the pathology of Parkinson's disease and L-DOPA induced dyskine-
sia, in the striatal glutamatergic synapse.
29
 These studies will be instrumental for the analysis of a possible novel role for Rph3A in the glu-
tamatergic synapse, involved in the regulation of NMDA receptor trafficking within the postsynaptic 
terminal.
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MATERIAL & METHODS
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I. Animals
 Animals used in this project were male C57/BL6 mice of 6 weeks, male Sprague-Dawley rats of 
6 weeks, E18 embryos from Sprague-Dawley rats for primary hippocampal neuron cultures, P6-P21 
Sprague-Dawley rat pups and 125-175g male Sprague-Dawley rats for 6-OHDA lesions. All the experi-
ments were approved by the OHSU Institutional Animal Care and Use Committee and by the Italian 
Health Ministry.
II. Cell cultures and transfections
 II.1. Cell lines (COS7)
 COS7 cells were grown on 100 mm dishes and maintained in Dulbecco's Modified Eagle's Me-
dium containing Glutamax (DMEM + Glutamax, GIBCO) supplemented with 10% Fetal Bovine Se-
rum and penicillin-streptomycin (GIBCO). Cells were allowed to grow till confluence before passaging 
every 3-4days using trypsin. The day before transfection, COS-7 cells were placed in a 6 wells multiwell 
(for cells lysis) or 12 wells multiwell (for imaging), then cells were transfected with 250-500 ng of plas-
mid DNA (for RFP-Rph3A, kind gift from Prof. Mitsunori Fukuda; RFP-Rph3A(673), was created by 
site-directed mutagenesis of Q673 into a stop codon; GluN2A-eGFP; GluN2A(1049)-eGFP, provided 
by Dr. Margarita Dinamarca from University of Milan; and/or PSD-95) using the lipofectamine 
method. After 36 hours COS-7 cells were lysed or fixed for immunostaining/imaging.
 II.2.1. Primary hippocampal neurons
 Hippocampal neuronal primary cultures were prepared from embryonic day 18-19 (E18-E19) rat 
hippocampi as previously described (Piccoli et al., 2007). Neurons were transfected at DIV9 with 2-4 
µg of plasmid DNA for RFP-Rph3A, kind gift from Prof. Mitsunori Fukuda; GluN2A-eGFP; GFP,a 
kind gift from Dr. Maria Passafaro from the University of Milan; shRph3A-tGFP, from Thermoscien-
tific or shScramble-tGFP, from Thermoscientific, using calcium-phosphate method. Neurons were 
treated at DIV15, lysed or fixed and then immunostained.
III. Triton Insoluble Fraction (TIF) and crude membrane fraction (P2) purifications
 From adult rat forebrain, hippocampus or striatum, Triton Insoluble Fraction (TIF), a fraction 
highly enriched in all categories of postsynaptic density proteins (i.e., receptor, signaling, scaffolding, 
and cytoskeletal elements) absent of presynaptic markers, was isolated. To obtain the TIF fractions, 
samples were homogenized at 4°C in an ice-cold buffer with protease inhibitors (Complete™, GE 
Healthcare, Mannheim, Germany), phosphatase inhibitors (PhosSTOPTM, Roche Diagnostics GmbH, 
Mannheim, Germany), 0.32 M Sucrose, 1 mM Hepes, 1 mM NaF, 0.1 mM PMSF, 1 mM MgCl2 using a 
hand held glass-teflon (for forebrain samples) or glass-glass homogenizer. An aliquot of homogenate 
(Homo) was kept for Western Blot (WB) analysis. Homo were then centrifuged at  1,000 g for 5 min at 
4°C, to remove nuclear contamination and white matter. The supernatant was collected and centrifuged 
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at 13,000 g for 15 min at 4°C. The resulting pellet (crude membrane) was resuspended in hypotonic 
buffer (1 mM Hepes with protease inhibitors (Complete™, GE Healthcare)). An aliquot of P2 was kept 
to perform coImmunoprecipitation (coIP) assay. P2 were then centrifuged at 100,000 g for 1 h at 4°C. 
Triton-X-100 extraction of the resulting pellet was carried out at 4°C for 20 min in an extraction buffer 
(1% Triton-X-100, 75 mM KCl and protease inhibitors (Complete™, GE Healthcare)). After extraction, 
the samples were centrifuged at 100,000 g for 1 h at 4°C and the TIFs obtained were resuspended in 20 
mM HEPES with protease inhibitors (Complete™, GE Healthcare).
 To get only the crude membrane fraction (P2), samples were homogenized at 4°C in an ice-cold 
buffer with protease inhibitors (Complete™, GE Healthcare), phosphatase inhibitors (PhosSTOPTM, 
Roche Diagnostics GmbH, Mannheim, Germany), 0.32 M Sucrose, 1 mM Hepes, 2 mM EDTA, 0.1 
mM PMSF using a hand-held glass-teflon (for forebrain samples) or glass-glass homogenizer. Homo 
were then centrifuged at 1,000 g for 10 min at 4°C, to remove nuclear contamination and white matter. 
The supernatants were collected and centrifuged at 100,000 g for 1 h at 4°C. The resulting pellet (crude 
membrane) obtained corresponds to the P2 fraction and the supernatant was discarded.
IV. Post-Synaptic Density purification
 To isolate PSDs from rat forebrain and hippocampus, a modification of the method of Carlin et 
al. (1980) was used. In brief, forebrain (from 4 rats) and hippocampus (from at least 12 animals) were 
rapidly dissected and pooled. Animals were killed, and brain areas were dissected within 2 min (Suzuki 
et al., 1994). Homogenization was carried out by 10 strokes in a hand-held glass-teflon (for forebrain 
samples) or glass-glass homogenizer in 4 volumes of cold 0.32 M sucrose containing 1 mM HEPES, 1 
mM MgCl2, 1 mM NaHCO3 and 0.1 mM phenylmethylsulfonyl fluoride (PMSF) (pH 7.4) in the pres-
ence of a complete set of protease inhibitors (CompleteTM; Boehringer Mannheim GmbH, Mannheim, 
Germany) and Phosphatase inhibitors (PhosSTOPTM, Roche Diagnostics GmbH, Mannheim, Ger-
many). The homogenized tissue was centrifuged at 1,000 g for 10 min. The resulting supernatant was 
centrifuged at 3,000 g for 15 min to obtain a fraction containing mitochondria and synaptosomes. The 
pellet was resuspended in 2.4 volumes of 0.32 M sucrose containing 1 mM HEPES, 1 mM NaHCO3, 
and 0.1 mM PMSF, overlaid on a sucrose gradient (0.85—1.0—1.2 M), and centrifuged at 82,500 g for 
2 h. The fraction between 1.0 and 1.2 M sucrose was removed, diluted with an equal volume of 1% 
Triton-X-l00 in 0.32 M sucrose containing 1 mM HEPES, 1 mM NaHCO3, and 0.1 mM PMSF, and 
stirred at 4°C for 15 mm. This solution was spun down at 82,500 g for 30 min. The pellet was resus-
pended, layered on a sucrose gradient (1.0—1.5—2.1 M), and centrifuged at 100,000 g at 4°C for 2 h. 
The fraction between 1.5 and 2.1 M was removed and diluted with an equal volume of 1% Triton-X-
100 and 150 mM KC1. PSDs were finally collected by centrifugation at 100,000 g at 4°C for 30min and 
stored at -80°C.
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V. Co-immunoprecipitation
 Rat forebrain/hippocampus/striatum aliquots of 150 µg of homogenate or of 50 µg of P2 frac-
tion or 5µg of TIF were incubated for 1 h at 4ºC in RIA buffer containing 200 mM NaCl, 10 mM 
ethylene-diamine-tetra-acetic acid (EDTA), 10 mM Na2HPO4, 0.5% NP-40, 0.1% sodium dodecyl sul-
phate (SDS) and  25 µl of protein A/G-agarose beads (Santa Cruz) in a final volume of 225 µl to pre-
clean the samples. The beads were then let to sediment at the bottom of the tube and the supernatant 
was collect. An antibody (Ab) against Rph3A or GluN2A was added to the supernatant before leaving 
to incubate overnight at 4ºC on a wheel. Protein A/G-agarose beads (Santa Cruz) were added and in-
cubation was continued for 2 hours, at room temperature on a wheel. Beads were collected by gravity 
and washed three times with RIA buffer before adding sample buffer for SDS-PAGE and boiling for 5 
minutes. Beads were collected by centrifugation, all supernatants were applied onto 7%-10% SDS-
PAGE and revealed by either anti-GluN2A, anti-GluN2B, anti-GluA1, anti-PSD-95, anti-Rph3A, anti-
SAP97, anti-MeOx2, anti-Rab3A, anti-Rab8, anti-Rab11, etc.
VI. Cloning, expression and purification of  glutathion-S-transferase (GST) fusion proteins
 The GluN2A subunit was subcloned downstream of glutathione S-transferase (GST) in the 
BaMHI and HindIII sites of the expression plasmid pGEX-KG by PCR using the Pfu polymerase 
(Stratagene) on a GluN2A cDNA template (kind gift from S. Nakanishi). Glutathione S-transferase 
(GST)-GluN2A C-terminal domain fusion protein containing the cytoplasmic domain of GluN2A 
(1049-1464 or 1349-1461 or 1244-1389) were expressed in Escherichia coli and purified on glutathione 
agarose beads (Sigma Aldrich, St. Louis, MO, USA) as previously described (Gardoni et al., 1999). 
Briefly, overnight cultures from single colonies of E. coli transformed with the plasmid were grown in 
50 ml of Luria-Bertani medium (Sigma, St. Louis, MO, USA) containing 100 µg/ml ampicillin (Sigma, 
St. Louis, MO, USA) at 37°C, diluted 1:10 with Luria-Bertani medium containing 100 µg/ml ampicillin 
and incubated under the same conditions for 2 h. Synthesis of recombinant proteins was induced by 
0.1 mM isopropyl-L-D-thiogalactopyranoside (Sigma, St. Louis, MO, USA), the bacteria were grown for 
another 4 h and harvested by centrifugation. Bacterial pellets were resuspended with ice-cold PBS (8.4 
mM Na2HPO4, 1.9 mM NaH2PO4, 150 mM NaCl, pH 7.4) containing 5 mM dithiothreitol (DTT), 
100 µg/ml lysozyme, 0.1 mM PMSF and incubated on ice for 15 min. Lysis was achieved by the addi-
tion of 1.5% N-laurylsarcosine (sarkosyl) from a 10% stock in PBS. Bacteria were sonicated on ice for 
1 min and the lysate was clarified by centrifuging at 10,000 g (5 min, 4°C) in a SS-34 rotor (Sorvall). Su-
pernatants were adjusted to 2% Triton X-100 and incubated with glutathione-agarose beads (50% v/v 
in PBS) for 2 h at room temperature. The beads were then extensively washed with ice-cold PBS.
VII. Pull-down assay
 250 µg of proteins were incubated with Tris Buffered Saline (TBS, 10 mM Tris and 150 mM 
NaCl) and 20 µl of GST to a final volume of 1 ml for 1 hour on the rotator at room temperature. 
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Samples were centrifuged at 3,000 rpm for 90 seconds and then the supernatant was collected (proteins 
that did not bind to GST). Proteins were incubated for 2 hours with 30-40 µl of GST fusion proteins 
of the C-terminal domain of GluN2A, PDZ1-2 or PZ3 domains of PSD-95 (plasmid DNA were gen-
erously provided by Prof. Yutaka Hata from Tokyo Medical and Dental University in Japan) or GST 
alone. After incubation beads were washed four times with TBS and 0.1% Triton X-100. Bound pro-
teins were resolved by SDS-PAGE and subjected to immunoblot analysis with polyclonal anti-Rph3A 
antibody or monoclonal anti-GST antibody.
VIII. Western Blotting
 15-30 µg of proteins from rat homogenate, subcellular fractions from brain or primary cultured 
hippocampal neurons or samples from coIP or GST-Pulldown Assay were separated on 7% or 10% 
SDS-PAGE gel, transferred to a nitrocellulose membrane and probed with the corresponding primary 
Ab, followed by incubation with horseradish peroxidase-conjugated secondary Ab. Membranes were 
developed using ClarityTM reagent (Biorad).
IX. Immunofluorescence
 Cells were fixed with 4% Paraformaldehyde (PFA)-4% sucrose in PBS solution at 4ºC and 
washed several times with PBS. Cells were either blocked with 5% BSA in PBS for 30min at room tem-
perature and then labeled with primary anti-Nterminal GluN2A antibody (Invitrogen), anti-Nterminal 
GluN2B (Neuromab) or anti-Nterminal GluA1 (Invitrogen) for surface labeling of GluN2A for 1 h at 
room temperature or permeabilized with 0.1% Triton-X-100 in PBS for 15min at room temperature 
and then blocked with 5%BSA in PBS for 30min at room temperature. Cells were then labeled with 
antibodies for intracellular epitopes (anti-Nterminal GluN2A, anti-Nterminal GluN2B or anti-
Nterminal GluA1 for total labeling; anti-Rph3A, EMC or Novus biological; anti-PSD-95, Neuromab; 
anti-Pan-shank, Neuromab) for 1 h at room temperature or overnight at 4ºC. Cells were washed and 
secondary antibody against appropriate specie conjugated with Alexa-488, Alexa-555 or Alexa-633 (in-
vitrogen) for 1 h at room temperature. Cells were then wash in PBS and mounted in Fluoromount 
(Sigma) or permeabilized for total labeling (following step are the same).
X. Point mutations
 RFP-Rph3A plasmid was a kind gift from Prof. Mitsunori Fukuda, from Tohoku University. This 
plasmid was used to perform point mutation inserting a stop codon for the codon corresponding to aa 
673 using following primers: 5'-CGCTGGCACCAACTGTAGAACGAGAACCACGTG-3’ (Forward) 
and 5’-CACGTGGTTCTCGTTCTACAGTTGGTGCAAGCG -3’ (Reverse).
XI. Electrophysiology
 Patch-clamp recordings of isolated NMDA-EPSCs or AMPA-EPSCs were performed of CA1 
hippocampal neurons from DIV12-16 organotypic cultured hippocampal slices from P7 rat pups using 
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a previously described protocol (Bellone & Nicoll, 2007). NMDA-EPSCs were isolated pharmacologi-
cally by adding 10 µM NBQX, 50 nM CPA and 10 µM Bicuculin to oxygenated ACSF bath solution 
and recordings were performed at +30mV to remove Mg2+ block of NMDAR. AMPA-EPSCs were 
isolated pharmacologically by adding 50 nM CPA and 10 µM Bicuculin to oxygenated ACSF bath solu-
tion and recordings were performed at -70mV were NMDAR are block by Mg2+. 1µM Scr or 2A-40 
peptide was added to the intracellular solution contained in the patch pipette. After obtain giga seal, to 
minimize run-up of baseline responses we waited 5min before entering whole-cell. Before breaking in, 
stimulation intensity was calibrated just below the threshold required to elicit an action potential moni-
tored in while in cell attached configuration (Bellone & Nicoll, 2007). After entering whole-cell, in the 
first 1-2min the intensity of stimulation was adjusted to have a similar staring amplitude with both pep-
tide. Recording was then started using 180 0.1Hz stimulation (30min). Electrophysiology experiments 
were carried out in the laboratory of Prof. Christophe Mulle and under the supervision of Dr. Mario 
Carta from IINS/Neurocentre Magendie, University of  Bordeaux II (France).
XII. DiI labeling for spine morphology
 Carbocyanine dye DiI (invitrogen) was used to label neurons as it is a lipophilic fluorescent mole-
cule. Protocol used for labeling has been previously described (B. G. Kim, Dai, McAtee, Vicini, & 
Bregman, 2007). DiI crystals were applied using a thin needle by delicately touching region of inter-
ested on both sides of 2 mm cortical slices prepared with cardiac perfusion of 1.5% PFA in PB 0.1 M. 
DiI was left to diffuse for 1 day in the dark at room temperature, then slices were fixed with 4% PFA in 
PB 0.1 M for 45min at 4ºC. 150 µm cortical slices were then obtain using a vibratome. The first slice 
was discarded. Slices were then mounted on glass slides with Fluoromount (Sigma) for confocal imag-
ing.
XIII. Rat model of  PD and LID
 XIII.1. 6-OHDA unilateral lesion in MFB (nigrostriatal)
 Male Sprague-Dawley rats were deeply anesthetized with Isofluorane and were injected with 6-
hydroxydopamine (6-OHDA, 12 µg/4 µl of saline containing 0.1% ascorbic acid) via a Hamilton sy-
ringe into the medial forebrain bundle, at a rate of 0.38 µl/min (AP = -4.4, L = + 1.2, VD = -7.5). Fif-
teen days later, the rats were tested with 0.05 mg/kg s.c. injection of apomorphine, and the contralat-
eral turns were counted for 40 min. Only the rats consistently making at least 200 contralateral turns 
(Schwarting & Huston, 1996) were used two months after the lesion, to avoid possible interference of 
apomorphine treatment with the plastic changes occurring in dopamine D2 receptors function follow-
ing chronic dopaminergic denervation. It has been demonstrated previously that rats meeting this 
screening criterion have 95% depletion of  striatal dopamine (Schwarting & Huston, 1996).
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 XIII.2. AIMs
 At 2 months after the 6-OHDA lesion, rats started to receive daily subcutaneous (s.c.) injections 
of 6 mg/kg L-DOPA plus 6 mg/kg benserazide for 14 days. L-DOPA-induced abnormal involuntary 
movements (AIMs) were recorded on alternate days three times per week using a validated rat AIM 
scale, as described previously (Cenci, Lee, & Björklund, 1998; Lundblad et al., 2002; Picconi et al., 
2003). Briefly, rat AIMs were classified into three subtypes: axial AIMs (i.e., dystonic posturing of the 
upper part of the body toward the side contralateral to the lesion), limb AIMs (i.e., abnormal move-
ments of the forelimb contralateral to the lesion), and orolingual AIMs (i.e., empty jaw movements and 
tongue protrusion). Each of these subtypes was scored on a severity scale from 0 to 4: 1, present dur-
ing less than half of the observation time (1 min); 2, present during more than half of the time; 3, pre-
sent all the time but was arrested by extern stimuli; 4, present all the time without possibility to arrest it. 
Ratings were performed at 20 – 180 min after L-DOPA injection.
 Each rat could reach a theoretical maximum AIM score of 80 in one session; each session con-
sisted of five monitoring periods, with a maximal score in each period of 16, and the total AIM score 
for each session was obtained by summing the monitoring period scores. The rats that reach more than 
AIM score of  20 per session were included in the dyskinetic group.
 Behavioral assessments of TAT-2A-40 treated dyskinetic rats and their controls were performed 
in double-blind conditions as some animals from the control dyskinetic group were stereotaxically in-
jected in ipsilateral striatum with sterile deionized H2O and operators were not aware of the status of 
the treatments.
XIV. Cell-permeable peptides design and use
 Each cell-permeable peptide (CPP) was manufactured by Bachem according to our designed se-
quences. Lyophilized CPPs were resuspended in sterile deionized H2O to a stock concentration of 1 
mM and stored at -20ºC. For treatment in cells, CPPs were simply added to the medium for a final con-
centration of 10 µM. In vivo treatments, were performed by injecting CPPs, as is, by subcutaneous (s.c.) 
or intraperitoneal (i.p.) at 3 nmol/g. 
 Intrastriatal injection was performed stereotaxically using 5 µl of the 1 mM stock (5 nmol) at a 
rate of  0.5 µl/min (AP=+0.2, L=+3.5, DV=-5.7).
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RESULTS & DISCUSSION
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I. Physiological conditions
 I.1. Rph3A is part of  the postsynaptic density
 As Rph3A was found as a new  putative interactor of GluN2A after yeast two-hybrid screening 
and is believed to be, from the literature, a presynaptic protein, it was important to first assess its sub-
cellular localization in order to confirm its interaction with GluN2A. If true, this interaction could only 
take place at the PSD since GluN2A is a postsynaptic protein. We found that Rph3A is widely present 
in different rat brain areas such as Cortex (Cx), Striatum (St), Hippocampus (Hp) and Cerebellum (Cb). 
We found comparable Rph3A protein levels in total homogenate and in a triton insoluble fraction 
(TIF), a postsynaptic density elements fraction, purified from all analyzed brain areas (Fig. 11A). To 
determine Rph3A enrichment into different subcellular compartments, we used a biochemical frac-
tionation approach to isolate purified postsynaptic densities (PSD) from rat brain tissues. We found the 
presence of Rph3A and P234-Rph3A (phosphorylated form of Rph3A at Ser234) in all subcellular 
fractions and the enrichment in synaptosomes (Syn), TIF and PSD fractions in both rat forebrain and 
hippocampus (Fig. 11A) similar to those of GluN2A, PSD-95 and Rab8, which are proteins present at 
the PSD. As expected, synaptophysin and Rab3A were present in all subcellular compartments analyzed 
but not in the TIF and PSD purified fractions as they are strictly presynaptic proteins. Similar data was 
found using fluorescent immunocytochemistry of primary cultured hippocampal neurons and confocal 
imaging, Rph3A was found co-localizing with PSD-95 (Fig. 11B) and endogenous GluN2A (Fig. 11C). 
Moreover, in neurons overexpressing Rph3A fused with RFP and GluN2A fused with eGFP, RFP-
Rph3A is found co-localizing with endogenous PSD-95 and GluN2A-eGFP (Fig. 11D). This result 
suggests that Rph3A is not a solely presynaptic protein, as described in the literature, but also a post-
synaptic protein where it could in fact interact with GluN2A and PSD-95.
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Fig. 11: Rph3A expression at PSD in rat brain.  (A) Distribution of Rph3A expression in rat brain and subcellular 
expression in rat forebrain and hippocampus.  H, homogenate; S1/2, supernatant 1/2; P1/2, pellet 1/2; Syn, 
Synaptosomal fraction; TIF, TritonX Insolyble Fraction; PSD, PostSynaptic Density fraction. (B) Fluorescent 
immunocytochemistry of Rph3A (green) and PSD-95 (red) in primary hippocampal neurons DIV15. On 6th panel 
(Merge) the colocalization points between Rph3A and PSD-95 are shown in white. Scale bars: 10µm. (C) Fluorescent 
immunocytochemistry of Rph3A (Red) and GluN2A (gree) in primary hippocampal neurons DIV15. Co-localization 
points are shown in whte on the merge panel. Scale bars: 10µm. (D) Fluorescent immunocytochemistry of PSD-95 (blue) 
in primary hippocampla neurons transfected with GluN2A-eGFP (green) and RFP-Rph3A (red). Co-localizing points 
between all three protein are seen in white on the merge panel. Scale bar: 5µm.
 I.2. Rph3A/GluN2A interaction
 The next step of our study was to characterize the interaction between Rph3A and GluN2A and 
assess the effect of its modulation. Firstly, clustering assay in heterologous COS7 cells was used to con-
firm the capability of GluN2A to interact with Rph3A and then co-immunoprecipitation assay was 
used to highlight the interaction in neurons. Secondly, a GST pull-down assay was used to identify the 
interaction domain of GluN2A with Rph3A. Thirdly, knowing the Rph3A interaction domain of 
GluN2A enabled use to design a cell-permeable peptide (CPP) able to disrupt the interaction to study 
the modulation of  the interaction.
  I.2.1. Characterization of  Rph3A/GluN2A interaction
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 As previously shown (Gardoni et al., 2003), in single transfection in COS7 cells GluN2A-eGFP 
and GluN2B-eGFP form perinuclear aggregates in the cytoplasm (Fig. 12A, top panels), without the 
GluN1 subunits GluN2s are incapable of trafficking to the plasma membrane. Co-transfection of 
RFP-Rph3A with GluN2A-eGFP caused a redistribution of GluN2A-eGFP throughout the cell. In 
fact, quantification of GluN2A-eGFP co-clustering with RFP-Rph3A shows a high co-localization 
value when compared with RFP-Rph3A/GluN2B-eGFP transfected cells (Fig. 12A & B; two-tailed t 
test, p=0.0003 *** n=9 cells). Accordingly, no effect on GluN2B-eGFP distribution was observed 
when co-transfected with RFP-Rph3A (Fig. 12A).
 To further confirm the interaction in neurons, we performed co-immunoprecipitation experi-
ments in total homogenate from rat primary hippocampal cultured neurons (Fig. 12C, PSD-95), P2 or 
TIF fractions from adult rat hippocampus (Fig. 12C). Anti-Rph3A immunoprecipitates were challenged 
in WB with GluN2A antibody showing the capability of Rph3A to interact with GluN2A specifically as 
no immunoreactivity was found with GluN2B. Interestingly, we found Rph3A to interact as well with 
PSD-95 (PSD-MAGUK family member, this interaction will be looked into further later on see I.3 of 
Results & Discussion) and Rab8, member of the Rab family of GTPases present at postsynaptic termi-
nals (Fig. 12C). Other Proteins were revealed to interact with Rph3A in this assay: CASK, MAGUK 
family member, known Rph3A interacting protein); CAMKII, known Rph3A interactor; and SAP-97. 
As a control for purity of the P2 fractions, Meox2, a nuclear protein, was used. It was not present in 
the input and no interaction was highlighted. As a control for purity of TIF fractions, Rab3A, a pre-
synaptic interactor of Rph3A, was used. It was not present in the input and no interaction was high-
lighted. Also, no interaction was found between GluA1 (AMPAR subunit) with Rph3A.
 Co-transfection in COS7 cells and pull-down assay were used to detect the GluN2A domain in-
volved in the binding with Rph3A. Co-transfection of RFP-Rph3A with a mutant plasmid of GluN2A 
where a stop codon was inserted at the position 1049 fused with eGFP (GluN2A(1049)-eGFP) re-
vealed a significant decrease of the co-localization degree when compared with co-transfection with the 
full length GluN2A-eGFP (Fig. 12E & F; two-tailed t test, p=0.0006 *** n=5-9 cells), suggesting that 
the GluN2A domain of interaction is comprised between aa 1049 and aa 1461. GST pull-down assay of 
Rph3A with fusion proteins with different length of the C-tail of GluN2A indicated that the aa 1349-
1389 region as key GluN2A domain involved in the interaction with Rph3A (Fig. 12D).
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Fig. 12: Characterization of Rph3A/GluN2A interaction. (A) Clustering assay in heterologous COS7 cells. Single 
transfection of GluN2A-eGFP, GluN2B-eGFP or RFP-Rph3A are shown in top panels. Co-transfection of RFP-Rph3A 
with GluN2A-eGFP is illustrated in middle panels and co-transfection of RFP-Rph3A with GluN2B-eGFP in bottom 
panels. (B) Bar graph representing percentage of GluN2s co-localizing with RFP-Rph3A. GluN2B-eGFP/RFP-Rph3A 
co-localization (two-tailed t test, p=0.0003 *** n=9 cells). (C) Co-Immunoprecipitation assay. Rph3A was immunoprecipi-
tated, from primary hippocampal neurons homogenate (WB: PSD-95, left panel), rat hippocampus homogenate (WB: 
CASK, left panel), rat hippocampus P2 purifications (left panel) and rat hippocampus TIF purification (right panel) and 
its interacting proteins were revealed by WB. (D) GST pull-down assay of Rph3A using C-terminal GluN2A GST fusion 
protein of 3 different sizes. (E) Co-transfection of RFP-Rph3A and mutant GluN2A(1049)-eGFP containing a stop co-
don at the 1049 aa position in COS7 cells. (F) Bar graph representing the percentage of GluN2A-eGFP or 
GluN2A(1049)-eGFP co-localizing with RFP-Rph3A (two-tailed t test, p=0.0006 *** n=5-9 cells).
  I.2.2. Modulation of  Rph3A/GluN2A interaction
 To assess the function of the Rph3A/GluN2A interaction, we firstly thought to use a specific 
shRNA (shRph3A) to knockdown the expression of Rph3A in hippocampal neurons. As Rph3A is a 
presynaptic and postsynaptic protein, using shRph3A would affect both pre- and postsynaptic Rph3A 
and therefore we wouldn't be able to segregate the results from a pre- or postsynaptic effect of Rph3A. 
As shown above, we managed to narrow domain the Rph3A interaction domain of GluN2A to aa 1349 
to aa 1389. Thus, we decided to use a different approach by designing a CPP containing that 40 aa se-
quence along with part of the HIV TAT sequence give the cell-permeability to the peptide (Fig. 13A) 
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that will called TAT-2A-40. This peptide is capable of disruption Rph3A/GluN2A interaction by 
binding Rph3A where GluN2A should have been able too as shown by co-immunoprecipitation assay 
of mice brain treated with CPP at 3nmol/g in i.p. for 1 h (Fig. 13B). After treating DIV 15 rat primary 
hippocampal neurons with 10µM of CPP for 30min, we found that the co-localization percentage be-
tween GluN2A and Shank (marker of the PSD) was significantly reduced in neurons treated with the 
active TAT-2A-40 compared to the control peptide containing the TAT sequence and a scramble of the 
Rph3 interaction domain of GluN2A sequence (TAT-Scr) (Fig. 13 C, left panel, & D; two-tailed t test 
p=0.0012 ** n=10-12 neurons). This effect was specific to GluN2A subunit as TAT-2A-40 had no ef-
fect on GluN2B/Shank co-localization (Fig. 13 C, right panel, & D; two-tailed t test p=0.6568 n=7-14 
neurons). These datas suggest that disrupting Rph3A/GluN2A interaction affects the synaptic localiza-
tion of  GluN2A.
Fig. 13: Rph3A/GluN2A interaction is important for the synaptic localization of GluN2A. (A) Sequence of 
TAT-2A-40, CPP capable of disrupting Rph3A/GluN2A interaction, and its control TAT-Scr, containing a scramble 
sequence of the 40 aa coresponding to the Rph3A interaction domain of GluN2A. (B) Co-Immunoprecipitation assay of 
Rph3A from mice brain P2 fractions treated with CPP at 3nmol/g i.p. for 1h. WB revealing GluN2A. (C) Fluorescent 
immunocytochemistry of GluN2A (left panel, green) or GluN2B (right panel, green) and Shank (PSD marker, red) in 
DIV15 rat primary hippocampal neurons treated with either TAT-2A-40 or TAT-Scr 10µM for 30min. Scale bar = 10µm. 
(D) Bar graph representing GluN2A/Shank or GluN2B/Shank co-localization percentage in DIV15 rat primary 
hippocampal neurons treated with either TAT-2A-40 or TAT-Scr 10µM for 30min (GluN2A/Shank: two-tailed t test, 
p=0.0012 ** n=10-12 cells; GluN2B/Shank: two-tailed t test, p=0.6568 n=7-14 cells).
 Furthermore, TAT-2A-40 significantly reduces the surface versus total expression ratio of 
GluN2A in DIV15 rat primary hippocampal neurons compared to the TAT-Scr control, of approxi-
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mately 40% of control mean (Fig. 14A & B; two-tailed t test p<0.0001 *** n=119-144 dendrites). Simi-
lar results were found when treating DIV15 rat primary hippocampal neurons with another CPP called 
TAT-2A that disrupts the interaction between GluN2A and PSD-95 (Vastagh et al., 2012) although the 
reduction was of a lesser amplitude, approximately 15% of control mean (Fig. 14C & D, two-tailed t 
test p=0.0003 *** n=33 dendrites). Not only Rph3A/GluN2A interaction is important for the synaptic 
localization of GluN2A but also for its surface expression in the same way as PSD-95/GluN2A inter-
action is. This is also shown by comparing the surface expression of GluN2A with a PSD marker, 
PSD-95. We found that TAT-2A-40 reduces significantly the surface synaptic expression of GluN2A of 
approximately 20% (Fig. 14E & F, two-tailed t test p<0.0001 *** n=119-144 dendrites). Disrupting 
Rph3A/GluN2A interaction affects the surface availability of GluN2A at the synapse, which should in 
turn affect the overall amplitude of  the NMDA response at glutamatergic synapses. 
 To assess NMDA response after modulation of Rph3A/GluN2A interaction, we performed 
patch-clamp recording of pharmacologically isolated NMDA excitatory postsynaptic currents (EPSCs) 
of CA1 neurons from DIV 12 cultured hippocampal organotypic slices using the 2A-40 peptide (and 
Scr control), but without the TAT sequence that gives the cell-permeability to the peptide, directly im-
plemented into the patch pipette with the intracellular solution giving us a single-cell postsynaptic tar-
geting. We observed that in presence of the 2A-40 peptide the NMDA EPSC was significantly de-
creased after 30 min of recording (Fig. 14G & H; two-tailed t test, p=0.0015 ** n=9 neurons), with no 
effect on decay time of the receptor (Fig. 14I; Scr 27'-30' vs 2A-40 27'-30' two-tailed t test, p=0.7558 
n=9 neurons). Therefore, disrupting Rph3A/GluN2A interaction affects the overall amplitude of 
NMDA EPSCs but not the kinetics of the receptor suggesting that there is less NMDAR available for 
activation at the synaptic plasma membrane.
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Fig. 14:  Rph3A/GluN2A interaction is important for GluN2A surface availability at the synapse. (A) Fluorescence 
immunocytochemistry of surface (red) and total (green) GluN2A after 30min CPP 10 µM treatment of DIV15 primary 
hippocampal neurons. Scale bar: 10 µm. (B) Bar graph representation of surface/total ratio percentage of mean TAT-Scr 
(two-tailed t test, p<0.0001 *** n=119-144 dendrites). (C) Fluorescence immunocytochemistry of surface (red) and total 
(green) GluN2A after 30min CPP 10 µM treatment of DIV15 primary hippocampal neurons. Scale bar: 10 µm. (D) Bar 
graph representation of surface/total ratio percentage of mean TAT-SDV (two-tailed t test, p<0.0001 *** n=119-144 
dendrites). (E) Fluorescent immunocytochemistry of surface GluN2A (red) and PSD-95 (blue) after 30min CPP 10 µM 
treatment of DIV15 primary hippocampal neurons. Scale bar: 10 µm. (F) Bar graph representation of surface GluN2A/
PSD-95 ratio percentage of mean TAT-Scr (two-tailed t test, p<0.0001 *** n=119-144 dendrites). (G) Normalized 
NMDA EPSCs over time in patch-clamp recordings with intracellular 2A-40 (blue) or Scr (red) peptides 1 µM or control 
without peptide (white) with representation of NMDA EPSCs at first stimulation and last (180th). (H) Bar graph repre-
sentation of the normalized NMDA EPSCs at the last stimulation (Two-tailed t test, p=0.0015 ** n=9 neurons). (I) Bar 
graph representation of  the decay time of  NMDA EPSCs in the first 3min and last 3min of  recording.
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 The effects of the TAT-2A-40 (or 2A-40) are specific to NMDAR, as it did not affect the AMPA 
EPSCs (Fig. 15C) nor the surface versus total expression ratio of GluA1, an AMPAR subunit (Fig. 15A 
& B; two-tailed t test, p=0.4062 n=39-51 dendrites). Moreover, the TAT-2A-40 peptide is specific to 
GluN2A subunit as it did not affect the surface versus total expression ration of GluN2B (Fig. 15D; 
two-tailed t test, p=0.1683 n=53-58 dendrites).
Fig. 15: Specificity of TAT-2A-40 on GluN2A-containing NMDARs. (A) Fluorescent immunocytochemistry of 
surface (red) and total (green) GluA1 after 30min CPP 10 µM treatment of DIV15 primary hippocampal neurons. Scale 
bar: 10 µm. (B) Bar graph representation of the GluA1 surface/total ratio percentage of mean TAT-Scr (two-tailed t test, 
p=0.4062 n=39-51 dendrites). (C) Normalized AMPA EPSCs over time in patch-clamp recordings with intracellular 2A-
40 (blue) or Scr (red) peptides 1 µM or control without peptide (white) with representation of AMPA EPSCs at first 
stimulation and last (180th). (D) Bar graph representation of the GluN2B surface/total ratio percentage of mean TAT-Scr 
(two-tailed t test, p=0.1683 n=53-58 dendrites).
 NMDAR subunit composition regulates receptor function and pharmacological responses. How-
ever, the role of distinct GluN2 subunits in dendritic spine remodeling has not yet been profoundly 
investigated. Accordingly, we investigated the onset of a possible effect of TAT-2A-40 on dendritic 
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spine morphology and density (Fig. 16A-D). As shown in Fig. 16A & B, treatment of mice with TAT-
2A-40 at 3 nmol/g i.p. for 2 h decreased significantly spine density in the hippocampus (~4 spines/10 
µm) compared to mice treated with the control peptide (~7 spines/10 µm; Fig. 16B; two-tailed t test, 
p=0.0184 * n=5 neurons, 780-860 µm). For a more detailed morphological analysis, the length, head 
width and neck width of the dendritic spines were measured and then, the spines were categorized ac-
cording to their shape (mushroom, thin and stubby; see Fig. 16D) using a highly validated classification 
method (K. M. Harris, Jensen, & Tsao, 1992). Although, we didn't find any significant difference in the 
total proportions of spines (data not shown) and of spine classes (Fig. 16D; two-tailed t tests n=5 neu-
rons, spines: p=0.3466, mushroom: p=0.6548, stubby: p=0.6908; thin: p=0.2329), we have highlighted 
a significant increase in spines head and neck widths of the TAT-2A-40 treated mice compared to 
TAT-Scr controls, and no difference in length (Fig. 16C; two-tailed t tests n=350-524 spines, length: 
p=0.3032, head width: p<0.0001 ***, neck width: p<0.0001 ***).
Fig. 16: Effect of TAT-2A-40 on dendritic spine density and morphology in the hippocampus. (A) DiI labeling of 
hippocampal neurons of CPP 3nmol/g i.p. treated mice for 2h. Scale bar: 5 µm. (B) Bar graph representation of spine 
density in these animals. (two-tailed t test, p=0.0184 * n=5 neurons, 780-860 µm of dendrite). (C) Bar graph 
representation of the measurements of spine length, head and neck width of CPP treated mice hippocampus. (D) Bar 
graph representation of  the proportion of  different spine classes of  these animals and schematic of  the spine classes.
 Similar data was found when down regulating the expression of Rph3A with an shRNA 
(shRph3A). Special attention was put in isolating a postsynaptic effect of this knockdown to the maxi-
mum of our abilities by using very low transfection efficacy of shRph3A and its scramble control 
(shScramble) allowing only a few transfected cells very distant from one another, with no visible con-
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tact. Primary hippocampal neurons transfected with the shRph3A at DIV 9 showed a decreased of 
GluN2A synaptic localization (GluN2A/Shank co-localization) at DIV 15 compared to shScramble 
transfected neurons (Fig. 17A; two-tailed t test, p=0.0011 ** n=17-19 neurons). No difference was 
found in GluN2B synaptic localization (Fig. 17A; two-tailed t test, p=0.9951 n=10-12 neurons). 
Moreover, neurons transfected with shRph3A showed a significantly lower spine density (~2 spines/10 
µm) than shScramble transfected neurons (~3.5 spines/10 µm; Fig. 17B; two-tailed t test, p=0.0053 *** 
n=7-8 neurons, ~3.1 mm).
Fig. 17: Knockdown of Rph3A.  (A) Bar graph representation of percentage of colocalization of GluN2A or GluN2B 
with Shank in DIV15 primary hippocampal cultured neurons transfected with shRph3A or its control, shScramble at 
DIV9. (B) Bar graph representation of  spine density in these neurons transfected with shRph3A or shScramble.
 Overall, these results show that Rph3A is not a solely presynaptic protein but also a postsynaptic 
one where it interacts with the GluN2A subunit of NMDAR. They suggest an important role of the 
Rph3A/GluN2A interaction in the surface availability of GluN2A at the synaptic membrane and there-
fore in the efficacy of hippocampal NMDAR as well as the overall spine density and morphology. 
Thus, postsynaptic Rph3A might have an important role in synaptic plasticity.
  I.2.3. Modulation of  Rph3A/GluN2A interaction and GluN2B/GluN2A developmental switch
 As explained previously (refer to paragraph I.3. of introduction), at birth in the hippocampus 
mainly GluN2B-containing NMDAR are present. This changes over time during development as switch 
in expression occurs in favor of GluN2A-containing NMDAR. This switch is crucial for the matura-
tion of the excitatory synapse. Since we demonstrated previously that Rph3A/GluN2A interaction is 
important for maintaining the surface availability of GluN2A-containing NMDAR at dendritic spines, 
we wondered whether we could affect the developmental switch of expression from GluN2B to 
GluN2A in the hippocampus by disrupting the Rph3A/GluN2A interaction.
 Therefore, we treated with the TAT-2A-40 or its control TAT-Scr three different groups of rat 
pups. The first group was treated with a single injection of the CPP at 3 nmol/g s.c. at P6, before the 
switch occurs, and then sacrificed at P15 for molecular analysis. The second group was treated with a 
chronic injection of the CPP at 3 nmol/g s.c. comprised of 5 injections starting at P6 and ending at 
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P14, the animals were then sacrificed at P15 for molecular and spine morphology analysis. The third 
group was treated chronically with the CPP following the same procedure as the second group but the 
animals were sacrificed at P21 for molecular analysis. After analysis of the hippocampal tissue, we 
found that there was a significant decrease of GluN2A expression at the PSD (TIF fractions) in TAT-
2A-40 treated pups from all groups compared their respective control (Fig. 18A & B; two-tailed t tests, 
1st group: TAT-2A-40 vs TAT-Scr p=0.0212 * n=5 , 2nd group: TAT-2A-40 vs TAT-Scr p=0.0340 * 
n=3-5, 3rd group: TAT-2A-40 vs TAT-Scr p=0.0230 n=3) with no changes of level of expression of 
Rph3A, GluN2B and PSD-95 (Fig. 18A & B; no statistical difference). However, we found a decrease 
of total PSD-95 expression in the hippocampus of TAT-2A-40 chronically treated pups from the sec-
ond group compared to their respective TAT-Scr controls (Fig. 18C; two-tailed t test, p=0.0026 ** n=3) 
while no such difference was found in the other two groups (data not shown). Moreover, the hippo-
campal spine morphology analysis of the TAT-2A-40 chronically treated from the second group 
showed a decreased spine density (~4 spines/10 µm) compared to control (~5.5 spines/10 µm; Fig. 
18D; two-tailed t test, p=0.0055 ** n=10-11 neurons, ~1.5-1.9 mm).
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Fig. 18: Modulating Rph3A/GluN2A interaction during GluN2B-to-GluN2A developmental switch in 
hippocampus.(A) Western blots of GluN2A, GluN2B, PSD-95, Rph3A and tubulin in hippocampal TIF purifications 
from rat pups traeted with TAT-Scr (Ctrl) or TAT-2A-40 (A) at 3nmol/g in s.c. "Single" corresponds to the group treated 
with a single injection at P6 and sacrificed at P15; "P21" corresponds to the group treated chronically with 5 injections 
from P6 to P14 and sacrificed at P21; "Chronic" corresponds to the group treated chronically with 5 injections from P6 
to P14 and sacrificed at P15. (B) Bar graph representations of GluN2A, Rph3A, GluN2B and PSD-95 percentage of 
respective TAT-Scr controls in TIF purifications from the 3 groups of animals treated with TAT-2A-40(GluN2A: 
two-tailed t tests, Single injection P6: p=0.0212 * n=5; 5 injections P6-P15: p=0.0340 * n=3-5; 5 injections P6-P15 
sacrifice P21: p=0.0230 n=3). (C) Bar graph representations of PSD-95 percentage of respective TAT-Scr controls in 
homogenates from the 3 groups of animals treated with TAT-2A-40(two-tailed t test, 5 injections P6-P15: p=0.0340 * 
n=3). (D) Bar graph representation of spine density in hippocampus of pups treated chronically with 5 injections from 
P6 to P14 (sacrifice at P15) with TAT-2A-40 or TAT-Scr 3nmol/g s.c.
 These results suggest that disrupting Rph3A/GluN2A interaction affected the synaptic maturity 
at a crucial developmental stage by reducing the synaptic availability of GluN2A and the overall spine 
density in the hippocampus. Thus, emphasizing the importance of postsynaptic Rph3A at the excita-
tory synapse.
 I.3. Rph3A/PSD-95 interaction
  I.3.1. Characterization of  Rph3A/PSD-95 interaction
 From the literature, it is known that Rph3A interacts with CASK, a PDZ-containing protein 
member of the MAGUK family (Y. Zhang et al., 2001). It is believed that the interaction occurs 
through the C2 domains of Rph3A. Looking at the sequence of Rph3A, we noticed that its last 4 aa 
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sequence (-VSSD) resembles a putative PDZ-binding motif which therefore could be the binding do-
main for CASK through its PDZ-domain but could also enable Rph3A to bind postsynaptic PDZ-
containing proteins such PSD-MAGUK family member like PSD-95.
 Using co-immunoprecipitation assay, we saw, as previously described (refer to I.2.1 of results and 
discussion), that Rph3A is capable of interacting with PSD-95 in primary hippocampal neurons (Fig. 
12C, left panel). With GST pull-down assay using GST fusion proteins of PDZ1-2 and PDZ3 domains 
PSD-95, we observed that Rph3A can bind PDZ1-2 and PDZ3 domains of PSD-95 with a higher af-
finity for PDZ3. It has been suggested before the GluN2 subunits interact with PDZ1-2 domains of 
PSD-95. Therefore, we hypothesize that GluN2A and Rph3A are not in competition with each other to 
bind PSD-95 but rather that they can bind simultaneously to form a putative GluN2A/Rph3A/PSD-95 
ternary complex.
  I.3.2. Modulation of  Rph3A/PSD-95
 In a similar manner as for the Rph3A/GluN2A interaction, we used two different approaches to 
verify the role of Rph3A C-tail in the interaction with PSD-95. At first, we transfected COS7 cells with 
PSD-95 and RFP-Rph3A full-length or RFP-Rph3A(673) (lacking the last 9 aa of the c-tail; see Fig. 
19D, top panels). Rph3A(673) showed a very low  co-localization value with PSD-95 suggesting the loss 
of interaction with the PSD-MAGUK protein (Fig. 19E; two-tailed t test, p=0.0014 ** n=8-9 cells). To 
confirm this result, we designed a cell-permeable TAT peptide containing the last 9 aa of Rph3A C-tail 
(TAT-Rph3A-9c) to compete with Rph3A for the binding to PSD-95. TAT-Rph3A(-VSSD) lacking the 
PDZ-interacting domain (VSSD), was used as control peptide (see sequences in Fig. 20A).
 We tested the effectiveness of the TAT-Rph3A-9c peptide in COS7 cells transfected with PSD-
95 and RFP-Rph3A at 10 µM for 1 h (Fig. 19D, bottom panels, & E). TAT-Rph3A-9c reduced signifi-
cantly the PSD-95/RFP-Rph3A co-localization score when compared with cells treated with control 
peptide (Fig. 19E; two-tailed t test, p=0.006 *** n=5-10 cells). These results indicate that Rph3A c-
terminal domain is responsible for Rph3A binding to PSD-95. 
 To verify whether disruption of Rph3A/PSD-95 binding could also affect GluN2A binding to 
Rph3A and/or PSD-95, we treated triple transfected COS7 cells with TAT-Rph3A-9c or TAT-Rph3a(- 
VSSD) peptides at 10 µM for 1 h. Interestingly, treatment with the active peptide was sufficient to de-
crease co-clustering of GluN2A-eGFP with both PSD-95 and RFP-Rph3A (Fig. 19F; two-tailed t tests, 
GluN2A-eGFP/RFP-Rph3A: p=0.0056 ** n=5 cells, PSD-95/RFP-Rph3A: p=0.0001 *** n=5 cells, 
GluN2A-eGFP/PSD95: p=0.0110 * n=5 cells), thus indicating a role of Rph3A in modulating 
GluN2A/PSD-95 interaction.
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Fig. 19:Rph3A interacts with PSD-95 and GluN2A. (A) GST pull down assay of Rph3A using GST fusion protein of 
PDZ1-2 and PDZ3 domains of PSD-95. (B) Confocal image of COS7 cell co-transfected with GluN2A-eGFP (green), 
RFP-Rph3A (red) and PSD95 (blue). Scale bar: 10 µm.(C) Schema of GluN2A/Rph3A/PSD-95 triple complex. (D) 
Clustering assays in heterologous COS7 cells co-transfected with PSD-95 and RFP-Rph3A or RFP-Rph3A(673), not 
treated or treated with TAT-Rph3A-9c or TAT-Rph3A(-VSSD). Scale bar: 10 µm. Sequences of CPPs are shown below 
images. (E) Bar graph representation of percentage of co-localization of PSD-95 and RFP-Rph3A with or without 
treatment with TAT-Rph3A-9c or TAT-Rph3A(-VSSD), 10 µM 1h, or PSD-95 and RFP-Rph3A(673). (F) Bar graph 
representation of percentage of co-localization GluN2A-eGFP and RFP-Rph3A, PSD-95 and RFP-Rph3A or 
GluN2A-eGFP and PSD-95 in COS7 transfected with all three plasmids and treated with TAT-Rph3A-9c or 
TAT-Rph3A(-VSSD) 10 µM 1h (two-tailed t tests, two-tailed t tests, GluN2A-eGFP/RFP-Rph3A: p=0.0056 ** n=5 cells, 
PSD-95/RFP-Rph3A: p=0.0001 *** n=5 cells, GluN2A-eGFP/PSD95: p=0.0110 * n=5 cells.
 In order to extend these observations to neuronal cells, we performed in vitro (cultured DIV15 
hippocampal neurons, 10 µM, 30min) as well as in vivo (6 week old C57BL6 mice, 3 nmol/g i.p., 1 h) 
treatments with TAT-Rph3A-9C or TAT-Rph3a(-VSSD) peptides. Subsequently biochemical and imag-
ing experiments were performed. In vivo treatment with TAT-Rph3A-9C reduces Rph3A co-
immunoprecipitation with both GluN2A and PSD-95 in forebrain P2 fractions (Fig. 20A & B; two-
tailed t tests, for GluN2A/Rph3A: p<0.0001 *** n=5 animals, for PSD95/Rph3A: p<0.0001 *** n=3 
animals and for PSD-95/GluN2A: p=0.0010 *** n=3 animals). The same treatment in vitro leads to a 
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significant decrease of GluN2A levels at synaptic sites, as indicated by the reduction of GluN2A co-
localization with the post-synaptic marker Shank (Fig. 20C & D; two-tailed t test, p=0.0069 ** n=10 
neurons). In addition, confocal analysis of GluN2A surface staining at synapses (ratio of integrated 
density of surface GluN2A in PSD-95 positive clusters) revealed a significant decrease induced by 
30min treatment with TAT-Rph3A-9c 10 µM (Fig. 20E & F; two-tailed t test, p=0.0005 *** n=51-100 
dendrites). Similarly, TAT-Rph3A-9C reduced total GluN2A surface staining (Fig. 20G & H; two-tailed 
t test, p=0.0130 * n=50 dendrites) indicating that the interaction of Rph3A with GluN2A/PSD-95 
complex is needed for a correct localization of GluN2A in the synaptic membrane. As expected, the 
same effect was obtained after treatment of hippocampal neurons with a peptide (TAT-2A) disrupting 
GluN2A/PSD-95 complex (refer to I.2.2 and Fig. 14C & D of  results & discussion).
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Fig. 20: Modulation of Rph3A/PSD-95 interaction. (A) Co-immunoprecipitation assay of Rph3A revealing as 
interacting proteins GluN2A and PSD-95 of forebrain P2 fractions of mice treated with CPPs 3 nmol/g i.p. for 1h. (B) 
Bar graph representation of percentage of immunoprecipitated Rph3A with GluN2A or PSD-95 and 
immunoprecipitated GluN2A and PSD-95 in TAT-Rph3A-9c treated mice compared to TAT-Rph3A(-VSSD) treated 
animals (two-tailed t tests, for GluN2A/Rph3A: p<0.0001 *** n=5 animals, for PSD95/Rph3A: p<0.0001 *** n=3 
animals and for PSD-95/GluN2A: p=0.0010 *** n=3 animals). (C) Fluorescent immunocytochemistry of GluN2A 
(green) and Shank (PSD marker, red) in DIV15 rat primary hippocampal neurons treated with either TAT-Rph3A-9c or 
TAT-Rph3A(-VSSD) 10µM for 30min. Scale bar = 10µm. (D) Bar graph representing GluN2A/Shank co-localization 
percentage in DIV15 rat primary hippocampal neurons treated with either TAT-Rph3A-9c or TAT-Rph3A(-VSSD) 10µM 
for 30min (two-tailed t test, p=0.0069 ** n=10 neurons). (E) Fluorescent immunocytochemistry of surface GluN2A (red) 
and PSD-95 (blue) after 30min CPP 10 µM treatment of DIV15 primary hippocampal neurons. Scale bar: 10 µm. (F) Bar 
graph representation of surface GluN2A/PSD-95 ratio percentage of mean TAT-Rph3A(-VSSD) (two-tailed t test, 
p=0.0005 *** n=51-100 dendrites) (G) Fluorescence immunocytochemistry of surface (red) and total (green) GluN2A 
after 30min CPP 10 µM treatment of DIV15 primary hippocampal neurons. Scale bar: 10 µm. (H) Bar graph representa-
tion of surface/total ratio of CPP treated DIV15 primary hippocampal neurons (two-tailed t test, p<0.0130 * n=50 den-
drites).
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 Furthermore, we investigated the onset of a possible effect of TAT-Rph3A-9c on hippocampal 
dendritic spines. In vitro treatment of GFP transfected primary hippocampal neurons with TAT-
Rph3A-9c (10 µM, 1 h) induced a significant reduction in dendritic spine density (Fig. 21; two-tailed t 
test, p=0.0019 ***).
Fig. 21: Dendritic spine density in TAT-Rph3A-9c treated primary hippocampal neurons. Bar grap representation 
of spine density DIV15 GFP transfected (DIV9) primary hippocampal neurons treated with TAT-Rph3A-9c or 
TAT-Rph3A(-VSSD) 10 µM 1h.
 These results suggest that Rph3A/PSD-95 interaction has an important role in the surface avail-
ability of GluN2A at the synaptic membrane and the overall spine density similarly as Rph3A/GluN2A 
interaction. Moreover, Rph3A/PSD-95 interaction is important for GluN2A/PSD-95 interaction em-
phasizing that the synaptic availability of GluN2A is dependent on the strength of GluN2A/Rph3A/
PSD-95 ternary complex.
II. Pathological conditions: Parkinson's disease and L-DOPA-Induced Dyskinesia
 In the striatum, glutamatergic cortical afferents converge with dopaminergic terminals from the 
substantia nigra pars compacta onto the dendritic spines of medium spiny neurons (MSNs). In particular, 
dopaminergic terminals form synaptic contacts in the neck of MSNs spines, whereas the head of the 
spine receives inputs from glutamatergic terminals (Surmeier et al., 2007). Consequently, dendritic 
spines of striatal MSNs are an essential site of information processing between glutamate and dopa-
mine both in physiological conditions and in neurodegenerative events, i.e. in Parkinson’s Disease (PD) 
(Gardoni et al., 2010). In addition, several studies described the co-localization of D1 and NMDA re-
ceptors in the MSNs dendritic spine indicating the existence of a direct molecular interaction and a 
functional cross-talk between the two receptor signaling pathways (Fiorentini, Gardoni, Spano, Di 
Luca, & Missale, 2003; Jocoy et al., 2011; Kruusmägi et al., 2009). As described earlier, NMDAR com-
position and localization is affected in PD and LID where an increased GluN2A/GluN2B ratio at syn-
apses and extrasynaptic GluN2B expression at striatal MSNs have been reported (refer to paragraph II.5 of 
Introduction) as well as changes of expression of Rph3A at different time points preceding overt neu-
ronal degeneration in PD and α-synucleinopathy (refer to paragraph V of  introduction).
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 Therefore, we believed the Rph3A/GluN2A interaction would be of significance in pathological 
conditions.
 Along with the alterations of NMDAR composition, we have found that the Rph3A/GluN2A 
interaction was significantly increased in both full 6-OHDA unilaterally lesioned (model of PD) and 
dyskinetic full 6-OHDA unilaterally lesioned treated with L-DOPA (model of LID) rats (Fig. 22A & B; 
two-tailed t tests: PD vs control p=0.012 @ n=6 animals, LID vs control p=0.0179 * n=6 animals) al-
though no changes in Rph3A expression in TIF purifications were seen in these animals (Fig. 22C & 
D). These results suggest a role of Rph3A/GluN2A complex in the pathology and therefore this inter-
action could be a good target to reduce dyskinesia in parkinsonian patients.
Fig. 22: Rph3A in Parkinson's disease and L-DOPA-induced dyskinesia. (A) Western blot of Rph3A from TIF 
purifications of the ipsilateral striatum from full 6-OHDA unilaterally lesioned rats (I), contralateral striatum of same 
animal (C, used as control) and ipsilateral striatum from dyskinetic full 6-OHDA lesioned rat treated with L-DOPA 
(DYS). (B) Bar graph representation of Rph3A expression percentage of mean Rph3A expression in contralateral 
striatum from full 6-OHDA unilaterally lesioned rats, from different animal: ipsilateral striatum from full 6-OHDA 
unilaterally lesioned rats (Ipsi Full), contralateral striatum from full 6-OHDA unilaterally lesioned rats (Contra Full) and 
ipsilateral striatum from dyskinetic full 6-OHDA unilaterally lesioned rats treated with L-DOPA (Ipsi Full Dusk). (C) 
Co-immunoprecipitation assay of Rph3A revealing GluN2A by western blot from P2 purifications of the ipsilateral 
striatum from full 6-OHDA unilaterally lesioned rats (I), contralateral striatum of same animal (C, used as control) and 
ipsilateral striatum from dyskinetic full 6-OHDA lesioned rat treated with L-DOPA (DYS). (D) Bar graph representation 
GluN2A/Rph3A co-immunoprecipitate percentage contralateral striatum in P2 fractions of ipsilateral striatum from full 
6-OHDA unilaterally lesioned rats (Ipsi Full), contralateral striatum from full 6-OHDA unilaterally lesioned rats (Contra 
Full) and ipsilateral striatum from dyskinetic full 6-OHDA unilaterally lesioned rats treated with L-DOPA (Ipsi Full 
Dusk). (two-tailed t tests: Ipsi Full vs Contra Full p=0.012 @ n=6 animals, Ipsi Full Dysk vs Contra Full p=0.0179 * n=6 
animals).
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 We have begun to test this hypothesis with an experiment where we measured the abnormal in-
voluntary movements score (AIMS) throughout the L-DOPA treatment of the full 6-OHDA unilater-
ally lesioned rats to assess the development and stabilization of LID (AIMS>~20). After 2 weeks of 
treatment, when the animals were considered to have developed LID, we stereotaxically injected the 
TAT-2A-40 peptide in dopamine-depleted striatum. The same day as the intrastriatal injection of TAT-
2A-40, the animals showed an almost complete disappearance of abnormal involuntary movements 
following L-DOPA treatment, characterizing those animals as no longer dyskinetics (Fig. 23; two-tailed 
t test, p=0.0028 ** n=4 animals). This effect was still observed following L-DOPA treatment one day 
after injection (Fig. 23, two-tailed t test, p=0.0043 ** n=4 animals), three days after injection (Fig. 23; 
two-tailed t test, p=0.0093 ** n=4 animals) and six days after injection (Fig. 23; two-tailed t test, 
p=0.0066 ** n=4 animals). Even if other experiments are needed to substantiate this TAT-2A-40 be-
havioral effect, these results already solidify the notion that postsynaptic Rph3A is involved in the syn-
aptic availability of GluN2A and therefore their interaction might be an interesting new target to tackle 
LID.
Fig. 23: Intrastriatal injection of TAT-2A-40 and LID. Graph representing AIM score of LID rats (6-OHDA-LID) 
and LID rats injected with TAT-2A-40 (5nmol) in ipsilateral striatum (6-OHDA-LID + TAT-2A-40) during L-DOPA 
treatment (once a day L-DOPA 6mg/kg + Benserazide 6mg/kg s.c.) before and after intrastriatal injection of TAT-2A-40 
peptide (two-tailed t tests; day 17: p=0.0028 ** n=4 animals, day 18: p=0.0043 ** n=4 animals, day 20: p=0.0093 ** n=4 
animals, day 23: p=0.0066 ** n=4 animals). Scoring was performed in double-blind conditions.
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CONCLUSION
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 It is known that GluN2A-containing NMDARs are stable at synapses. On the other hand, 
GluN2B-containing NMDARs are known to be a more mobile pool of NMDAR at the synapse but 
also mobile from and to extrasynaptic sites (Groc et al., 2006). However, only the interaction with PSD-
95 has been clearly demonstrated to favor GluN2A surface expression and stabilization within the syn-
aptic membrane. Indeed, in search of the molecular mechanism(s) that mediate these differential 
GluN2-NMDAR distributions in synapses, PSD-95 family proteins emerged as primary candidates. 
SAP102 co-localizes with GluN2B subunit at the periphery of the synapse whereas PSD-95 co-
localizes preferentially with the GluN2A subunit (J. Zhang & Diamond, 2009). Moreover, immunopre-
cipitation experiments from hippocampus extracts revealed that GluN2B subunit preferentially inter-
acts with SAP102 and the GluN2A subunit with PSD-95 (Sans et al., 2000). However, this view is chal-
lenged by a biochemical study showing that the isolated di-heteromeric receptors GluN1/GluN2A and 
GluN1/GluN2B interact with similar affinities with PSD-95, SAP102 and PSD-93 (Al-Hallaq et al., 
2007). Therefore, preferential associations between GluN2 subunits and specific PSD proteins in syn-
apses may not only depend on their affinities but also to other molecular processes that remain to be 
identified. In this context, even if the literature reported extensive studies describing the differential 
role of GluN2B-containing receptors at synaptic and extrasynaptic sites and identified relevant protein 
partners regulating their synaptic localization, much less is known for GluN2A-containing receptors.
 For this reason, our lab was interested in studying the molecular mechanisms regulating the syn-
aptic targeting of GluN2A-containing receptors that are far from being understood. Based on these 
considerations, we decided to study the modulation of the GluN2A subunit in the synapse starting 
from the identification of new GluN2A-interacting proteins. Our lab recently performed a yeast two 
hybrid screening of a brain cDNA library using GluN2A(839-1461) as bait, without the last 3 aa (SDV) 
of the PDZ-binding domain. Among the new putative GluN2A-binding proteins, we found Rph3A. 
Co-clustering assays in COS-7 cells, co-immunoprecipitation and pull-down assays confirmed Rph3A 
interaction with GluN2A(1349-1389) C-terminal domain. Incubation of primary neurons with a CPP 
containing the GluN2A domain aa 1349-1389 (TAT-2A-40) and competing with the endogenous 
GluN2A subunit for Rph3A binding, led to a significant reduction in the levels of surface and synaptic 
GluN2A and consequently to a reduction of NMDAR activity. Notably, no effects on the synaptic lo-
calization of the GluN2B subunit were observed, nor did we see any effect on AMPAR synaptic avail-
ability or activity. Analysis of Rph3A C-terminal domain revealed the presence of a putative PDZ-
interacting domain (-VSSD). Co-clustering assays in COS-7 cells and co-immunoprecipitation experi-
ments from neuronal lysates confirmed that Rph3A i) binds also to the scaffolding protein PSD-95 and 
ii) forms a triple complex with GluN2A and PSD-95 at the excitatory postsynaptic density. Disruption 
of GluN2A/Rph3A or PSD-95/Rph3A interactions led to a similar decrease in the synaptic levels but 
also the surface levels of GluN2A-containing NMDARs with a concomitant disruption of GluN2A/
PSD-95 complexes. 
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 Altogether these results suggest that GluN2A/PSD-95/Rph3A complex formation is required 
for a correct localization and stabilization of GluN2A-containing NMDARs at the synapse. However, 
the fact that Rph3A binds to Myosin Va cargo protein (Brozzi et al., 2012), known to catalyze the 
transport of AMPARs into dendritic spines during activity-dependent synaptic plasticity, does not ex-
clude Rph3A from being involved in the trafficking of GluN2A. This remains an important issue to be 
addressed. Overall, even if previous studies report only a presynaptic role for Rph3A in the regulation 
of vesicle trafficking via interaction small GTPases of the Rab family, cytoskeletal proteins, MAGUK 
scaffolding proteins and phospholipids (Shirataki et al., 1992; Shirataki et al., 1994; Yamaguchi et al., 
1993; Fukuda et al., 2004; Kato et al., 1996; Südhof, 1997; Burns et al., 1998), our work has highlighted 
the presence of Rph3A at postsynaptic terminal and a role in synaptic availability of GluN2A NMDAR 
subunit.
 The subunit composition of NMDARs is not static but changes during development in response 
to neuronal activity or sensory experiences. This plasticity, which was long thought to occur exclusively 
during development, can also occur at adult synapses. Changes in subunit composition can be rapid 
(timescale of minutes) and can have profound influences on the functioning of synapses and networks. 
Several studies in vitro and in vivo indicate that a change in the ratio of GluN2A to GluN2B, as occurs 
during sensory experience, affects subsequent NMDAR-dependent synaptic modifications. Manipula-
tions of the GluN2A-to-GluN2B ratio, either through pharmacological means (Xu et al., 2009) or 
activity-dependent alterations (Philpot, Cho, & Bear, 2007; M.-C. Lee, Yasuda, & Ehlers, 2010), regulate 
both the magnitude and sign of  subsequent plasticity, leading to a shift in the LTP and LTD threshold.
 Here, we have used the developmentally driven changes in the GluN2A-to-GluN2B ratio as a 
paradigm to study the functional role of Rph3A in regulating the abundance of GluN2A available at 
postsynaptic terminals. The chronic treatment (from P6 to P14) with TAT-2A-40, disrupting Rph3A/
GluN2A interaction, has led to a decrease of GluN2A present in the PSD preventing the developmen-
tal change in NMDAR composition; thus emphasizing on the role of Rph3A in the synaptic localiza-
tion of  GluN2A.
 Moreover, in all our experimental paradigms we have observed an effect of the disruption of 
Rph3A/GluN2A complexes or even the knockdown of Rph3A on the dendritic spine density in hip-
pocampal neurons. This is a comparable result to another study on IQGAP1, a GluN2A binding pro-
tein, and more precisely on IQGAP1-/- primary hippocampal neurons where researchers observed a 
reduced expression of surface GluN2A as well as a reduction in spine density (Gao et al., 2011). Other 
studies have also shown that synaptic NMDAR activation is also a trigger for genomic processes that 
increase the transcription of neuroprotective genes like BDNF (Schulz, Siemer, Krug, & Höllt, 1999; 
Cammarota et al., 2000; Hardingham et al., 2002) that leads to the sprouting of dendrites in many areas 
of the brain, such as CA1 in the hippocampus (Grande, Fries, Kunz, & Kapczinski, 2010; Tyler & 
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Pozzo-Miller, 2003) and that inhibition of either GluN2A- or GluN2B-containing NMDARs signifi-
cantly decreases BDNF expression (X. Zhou, Ding, Chen, Yun, & Wang, 2013). Also a decrease in 
BDNF expression reduces spine density in these areas (Rothman & Mattson, 2013). Although, there is 
no real understanding of the role of GluN2A in spine density or spine morphology in the hippocam-
pus.
 In the last decade, several studies indicated that dysfunction of the glutamatergic transmission 
plays a key role in both Parkinson's disease (PD) and L-DOPA-induced dyskinesia (LID) (Calabresi et 
al., 2011). Particularly, changes in the corticostriatal glutamatergic transmission have been reported in 
animal models of PD and LID (Sgambato-Faure & Cenci, 2012; Mellone & Gardoni, 2013), as well as 
in PD patients at different disease stages (Ahmed et al., 2011). After chronic L-DOPA treatment, the 
glutamatergic signaling from the cortex to the striatum undergoes adaptive changes, which result in the 
aberrant functioning of NMDAR at the dendritic spines of striatal medium spiny neurons (Sgambato-
Faure & Cenci, 2012). In the past ten years, clinical trials focused on the classical pharmacological ap-
proach based on NMDAR antagonists to reduce the receptor activity. Among others, amantadine ex-
hibits anti-dyskinetic activity (Sawada et al., 2010), even if its beneficial effect is attenuated after a few 
months. A recent meta-analysis confirmed the short-term benefits of amantadine in the treatment of 
dyskinesia (Elahi et al., 2012). Besides NMDAR overactivation, abnormal NMDAR trafficking, which 
results in the modification of the receptor subunit composition at the synapse, has been involved in the 
pathogenesis of several brain disorders (Sanz-Clemente, Nicoll, & Roche, 2012). In particular, a great 
amount of studies have addressed the role of expression, phosphorylation state, and synaptic distribu-
tion of the specific subtypes of NMDARs in LID (Sanz-Clemente et al., 2012; Gardoni et al., 2010). 
Our group demonstrated the alterations in synaptic NMDAR GluN2A/GluN2B subunit ratio in the 
striatum correlates with the motor behavior abnormalities observed in rat models of PD and LID 
(Gardoni et al., 2006; Gardoni et al., 2011). Notably, these findings have been confirmed in the striatum 
of dyskinetic monkeys (Gardoni et al., manuscript in preparation) and in dyskinetic PD patients com-
pared to age-matched control subjects (Gardoni et al., manuscript in preparation). Importantly, we 
showed that prevention of the aberrant NMDAR GluN2A/GluN2B subunit ratio at the striatal excita-
tory synapse is sufficient to significantly reduce the onset of LID in L-DOPA-treated parkinsonian 
animals (Gardoni et al., 2011). In particular, the concomitant systemic treatment with L-DOPA and 
TAT-2A, a CPP able to interfere with the interaction between GluN2A subunit and the scaffolding 
protein PSD-95, reduces the percentage of parkinsonian rats developing LID (Gardoni et al., 2011) and 
ameliorates the dyskinetic behavior in L-DOPA treated MPTP-monkeys (Gardoni et al., manuscript in 
preparation). Altogether these data support the importance of a correct balance NMDAR subunits at 
the striatal synapse to counteract the phenotype/molecular changes in PD and LID.
 Based on the above-mentioned considerations and taking into account the well-known limitations 
in the use of classical NMDAR antagonists, we are aiming at restoring the physiological ratio between 
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GluN2A and GluN2B subunits to reduce dyskinetic behaviors by acting on the synaptic surface avail-
ability of GluN2A-containing NMDARs through its interaction with Rph3A. This approach has the 
advantage of manipulating the subunit composition of synaptic NMDARs, meaning a reduction of 
synaptic GluN2A-containing NMDARs, rather than a more generalized antagonism of both synaptic 
and extrasynaptic receptors.
 As described in this work, we have found an increased between Rph3A and GluN2A in 6-
OHDA-lesioned rats and L-DOPA treated dyskinetic animals. These data are consistent with the previ-
ously described increase in synaptic GluN2A-containing NMDARs in the same animal models (Gar-
doni et al., 2010; Gardoni et al., 2006). Finally, a pilot experiment in a small group of animals demon-
strated that intrastriatal injection of TAT-2A-40 peptide in L-DOPA-treated rats resulted in a highly 
significant decrease of their dyskinetic behavior. Accordingly, it would be of relevance to test TAT-2A-
40 in chronic treatments for long-term effects but also in systemic treatments with L-DOPA to reduce 
the onset of LID itself in order to go towards a clinical application. In addition, it  would be relevant to 
test Rph3A as target not only in LID but also in PD itself, considering that we saw a huge increase of 
Rph3A/GluN2A interaction also in untreated parkinsonian animals. Interestingly, a significant increase 
of GluN2A-containing NMDAR was found in animals with a partial lesion, model of early stages of 
PD, thus supporting the use of peptides disrupting Rph3A/GluN2A at this stage of the disease. For 
example, it has been shown recently that an analogous peptide (TAT-2A targeting GluN2A-containing 
NMDARs interaction with PSD-95) improved the motor skills in these rats (Paillé et al., 2010).
 Thus, our work has put forward a possible novel therapeutic strategy to counteract LID by reduc-
ing the synaptic levels of GluN2A-containing NMDARs at the corticostriatal synapses. Interestingly, an 
analogous peptide (TAT-2A targeting GluN2A-containing NMDARs interaction with PSD-95) when 
applied to animal models of LIDs, in concomitant treatment with L-DOPA reduced the onset of 
dyskinesia (Gardoni et al., 2011; Gardoni et al., manuscript in preparation). Despite the debated clinical 
applicability of CPPs due to pharmacokinetic and pharmacoeconomic reasons, key results on CPPs 
have been recently obtained both at preclinical and clinical stages (Gardoni et al., 2011; Hill et al., 
2012), clearly supporting the therapeutic relevance of this innovative pharmacological approach. In 
particular, a peptide differing from only 2 aminoacids (aa) (TAT-GluN2B9c, targeting GluN2B-
containing NMDARs interaction with PSD-95) has been used successfully in phase 2 randomized 
double-blinded placebo-controlled clinical trial for stroke (Hill et al., 2012). Such findings reinforce the 
applicability of interference peptides in central nervous system disorders and pave the way for future 
applications in clinical trials. In addition, the production of small and potent plasma-stable peptidomi-
metic compounds deriving from CPPs can represent the possibility of a further improvement and a 
more favorable and affordable clinical applicability of this therapeutic intervention strategy (Bach et al., 
2011).
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ABBREVIATIONS
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6-OHDA: 6-hydroxydopamine
ABD: agonist binding domain
AD: Alzheimer's disease
AMPA: 3-hydroxy-5-methyl-4-isoxazole proprionic acid
AP: Anterio-posterior coordonates
APP: amyloid precursor protein
Aβ: β-amyloid
BR-MyoVa: brain-spliced isoform of  Myosin Va
Ca2+: calcium
CAMKII: Ca2+-calmodulin kinase II
Cb: Cerebellum
CNS: central nervous system
coIP: coImmunoprecipitation
CPP: cell-permeable peptide
CTD: C-terminal domain
Cx: Cortex
DA: dopaminergic/dopamine
DIV: day in vitro
DV: dorso-ventral coordinates
E: embryonic stage day
eGFP: enhanced green fluorescent protein
EPSC: excitatory postsynaptic current
ER: endoplasmatic reticulum
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fEPSCP: field excitatory postsynaptic potential
GFP: green fluorescent protein
GluN: subunit of  NMDAR
H or Homo: homogenate
HD: Huntington's disease
Hp: Hippocampus
htt: huntingtin
i.p.: intraperitoneal
iGluR: ionotropic glutamate receptor
Ip3: inositol-1,4,5-trisphosphate
K+: potassium
KA: kainate
L: lateral coordinate
L-DOPA: L-3,4-dihydroxyphenylalanine (also levodopa)
LID: L-DOPA-Induced Dyskinesia
LTP: long term potentiation
MAGUK: membrane-associated guanylate kinase
Mg2+: magnesium
mGluR: metabotropic glutamate receptor
mhtt: Mutated htt
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MSN: medium spiny neurons
Na+: sodium
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NMDA: N-methyl-D-aspartate
NMDAR: NMDA receptor
nNOS: nitric oxide synthase
NTD: N-terminal domain
P2: crude membrane fraction (pellet 2)
P234-Rph3A: phosphorylated form of  Rph3A at Ser234
P: postnatal day
PD: Parkinson's disease
PIP2: Phosphatidylinositol-4,5-bisphosphate
PSD: postsynaptic density
Ras-GRF1: Ras-guanine nucleotide-releasing factor
RasGAP: Ras GTPase activating protein
RFP: red fluorescent protein
Rph3A: Rabphilin3A
s.c.: subcutaneous
SGs: secretory granules
SNARE: soluble N-ethylmaleimide-sensitive factor attachment protein receptor
St: Striatum
STEP: striatal enriched tyrosine phosphatase
Syn: synaptosomes
tGFP: turbo GFP
TIF: Triton-X-100 Insoluble Fraction
TMD: transmembrane domain
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